

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents  
 United States Patent and Trademark  
 Office  
 Box PCT  
 Washington, D.C. 20231  
 ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

<b>Date of mailing</b> (day/month/year) 20 April 2000 (20.04.00)	
<b>International application No.</b> PCT/SE99/01230	<b>Applicant's or agent's file reference</b> 2996317
<b>International filing date</b> (day/month/year) 06 July 1999 (06.07.99)	<b>Priority date</b> (day/month/year) 06 July 1998 (06.07.98)
<b>Applicant</b> HANSON, Lars, Å. et al	

1. The designated Office is hereby notified of its election made:



in the demand filed with the International Preliminary Examining Authority on:

03 February 2000 (03.02.00)



in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

<b>The International Bureau of WIPO</b> 34, chemin des Colombettes 1211 Geneva 20, Switzerland  Facsimile No.: (41-22) 740.14.35	Authorized officer  Claudio Borton  Telephone No.: (41-22) 338.83.38
--	--

1  
INTERNATIONAL SEARCH REPORT

International application No.  
PCT/SE 99/01230

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>				
<b>IPC6: C07K 14/79, A61K 38/40</b> According to International Patent Classification (IPC) or to both national classification and IPC				
<b>B. FIELDS SEARCHED</b>				
Minimum documentation searched (classification system followed by classification symbols)				
<b>IPC6: C07K</b>				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
<b>SE,DK,FI,NO classes as above</b>				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)				
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	<b>WO 9806425 A1 (HOLDINGBOLAGET VID GÖTEBORGS UNIVERSITET AB), 19 February 1998 (19.02.98)</b>  --	1-47		
X	<b>STN International, File ZCAPLUS, ZCAPLUS accession no. 1995:746299, Document no. 123:138157, Morinaga Milk Industry Co Ltd: "Preparation and purification of antibiotic"; &amp; JP,A2,07145196, 19950606</b>  --	1-8,21-28,38		
X	<b>STN International, File ZCAPLUS, ZCAPLUS accession no. 1996:268163, Document no. 124:298949, Senju Pharma Co: "Pharmaceutical compositions containing lactoferrin-derived peptides for treatment of cornea"; &amp; JP,A2,08040925, 19960213</b>  --	1-8,27-28,38		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.				
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top;">           * Special categories of cited documents:            "A" document defining the general state of the art which is not considered to be of particular relevance            "E" earlier document but published on or after the international filing date            "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)            "O" document referring to an oral disclosure, use, exhibition or other means            "P" document published prior to the international filing date but later than the priority date claimed         </td> <td style="width: 50%; vertical-align: top;">           "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention            "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone            "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art            "&amp;" document member of the same patent family         </td> </tr> </table>			* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family			
Date of the actual completion of the international search		Date of mailing of the international search report		
28 October 1999		04.11.1999		
Name and mailing address of the ISA: Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86		Authorized officer  Carolina Gómez Lagerlöf/Eö Telephone No. +46 8 782 25 00		

2  
INTERNATIONAL SEARCH REPORT

International application No.  
PCT/SE 99/01230

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	STN International, File ZCAPLUS, ZCAPLUS accession no. 1996:42900, Document no. 124:78745, Morinaga Milk Industry Co Ltd: "Plasmid vectors for recombinant production of antibacterial peptide lactoferricin"; & JP,A2,07274970, 19951024  --	1-8,27,38
X	STN International, File ZCAPLUS, ZCAPLUS accession no. 1997:449119, Morinaga Milk Industry Co., Ltd. "Antifungal agents containing azole fungicides and lactoferrin hydrolyzates"; & JP,A2,09165342, 19970624  --	1-8,27,38
X	STN International, File ZCAPLUS, ZCAPLUS accession no. 1996:353198, Document no. 125:34176, Koga, Yasuhiro: "Preparation of lactoferrin-related peptides as immunostimulants"; & JP,A2,08073499, 19960319  --	1-12,27-47
X	STN International, File ZCAPLUS, ZCAPLUS accession no. 1996:113395, Document no. 124:185550, Morinaga Milk Industry Co Ltd: "Anticancer parenteral compositions containing lactoferrin-related peptides"; & JP,A2,07309771, 19951128  --	1,9-12,27-47
X	US 5565425 A (NAOKI YAMAMOTO ET AL), 15 October 1996 (15.10.96)  --	1,9-47
X	STN International, File ZCAPLUS, ZCAPLUS accession no. 1996:497256, Document no. 125:132783, Morinaga Milk Industry Co Ltd: "Lactoferrin-derived peptides as antiulcer drugs"; JP,A2,08143468, 19960604  --	1,9-47

3  
INTERNATIONAL SEARCH REPORT

International application No.  
PCT/SE 99/01230

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9806424 A1 (MORINAGA MILK INDUSTRY CO., LTD.), 19 February 1998 (19.02.98)  --	1,9-47
X	Infection and Immunity, Volume 66, No 6, 1998, Daniel S. Chapple et al, "Structure-Function Relationship of Antibacterial Synthetic Peptides Homologous to a Helical Surface Region on Human Lactoferrin against Escherichia coli Serotype 0111", page 2434 - page 2440, see HLP1 and HLP2  --	1,13-20
X	FEBS Letters, Volume 382, 1996, Edward W. Odell et al, "Antibacterial activity of peptides homologous to a loop region in human lactoferrin", page 175 - page 178, see HLT1 and HLT2  --	1,13-20
X	US 5304633 A (MAMORU TOMITA ET AL), 19 April 1994 (19.04.94)  -- -----	1,13-47

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/SE99/01230

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 48-57  
because they relate to subject matter not required to be searched by this Authority, namely:  
see next sheet
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see next sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

## Box I

Claims 48-57 relate to methods of treatment of the human or animal body by surgery or by therapy/ diagnostic methods practised on the human or animal body/Rule 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.

## Box II

The claims disclose peptides that are based on the sequence constituted of the amino acids 12-40 of human lactoferrin. Such peptides are previously known in the art.

The claims can be divided into different groups, which refer to different parts of human lactoferrin.

Claims 1-8

Claims 9-12

Claims 13-20

Claims 21-26.

There is no technical relationship between these groups, because the claims do not share any special technical features that not are known in the prior art.

The claims do not form a single general inventive concept, see PCT Rule 13.1.

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

28/09/99

International application No.  
**PCT/SE 99/01230**

Patent document cited in search report			Publication date	Patent family member(s)			Publication date
WO	9806425	A1	19/02/98	AU	3872797	A	06/03/98
				EP	0920331	A	09/06/99
US	5565425	A	15/10/96	EP	0643074	A	15/03/95
				JP	6256211	A	13/09/94
WO	9806424	A1	19/02/98	JP	10059864	A	03/03/98
US	5304633	A	19/04/94	AU	645342	B	13/01/94
				AU	8370491	A	12/03/92
				CA	2050786	A,C	08/03/92
				DE	69129395	D,T	17/12/98
				DK	474506	T	02/06/98
				EP	0474506	A,B	11/03/92
				SE	0474506	T3	
				JP	2818056	B	30/10/98
				JP	5092994	A	16/04/93

# PATENT COOPERATION TREATY

## PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 2996317	<b>FOR FURTHER ACTION</b>	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/SE99/01230	International filing date (day/month/year) 06.07.1999	Priority date (day/month/year) 06.07.1998
International Patent Classification (IPC) or national classification and IPC <sub>7</sub> C 07 K 14/79, A 61 K 38/40		
Applicant A+ Science Invest AB et al		

1.	This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2.	This REPORT consists of a total of <u>5</u> sheets, including this cover sheet.
<input checked="" type="checkbox"/>	This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).
	These annexes consist of a total of <u>6</u> sheets.
3.	This report contains indications relating to the following items:
I	<input checked="" type="checkbox"/> Basis of the report
II	<input type="checkbox"/> Priority
III	<input checked="" type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
IV	<input type="checkbox"/> Lack of unity of invention
V	<input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
VI	<input type="checkbox"/> Certain documents cited
VII	<input type="checkbox"/> Certain defects in the international application
VIII	<input type="checkbox"/> Certain observations on the international application

Date of submission of the demand  03.02.2000	Date of completion of this report  09.11.2000
Name and mailing address of the IPEA/SE Patent- och registreringsverket Box 5055 S-102 42 STOCKHOLM Facsimile No. 08-667 72 88	Authorized officer  Carolina Gómez Lagerlöf/GH Telephone No. 08-782 25 00



# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/SE99/01230

## I. Basis of the report

### 1. With regard to the elements of the international application:\*

- ☐ the international application as originally filed
- ☒ the description:  
 pages 1-41, as originally filed  
 pages \_\_\_\_\_, filed with the demand  
 pages \_\_\_\_\_, filed with the letter of \_\_\_\_\_
- ☒ the claims:  
 pages \_\_\_\_\_, as originally filed  
 pages \_\_\_\_\_, as amended (together with any statement) under article 19  
 pages \_\_\_\_\_, filed with the demand  
 pages 1-51, filed with the letter of 29.09.2000
- ☒ the drawings:  
 pages 1-5, as originally filed  
 pages \_\_\_\_\_, filed with the demand  
 pages \_\_\_\_\_, filed with the letter of \_\_\_\_\_
- ☐ the sequence listing part of the description:  
 pages \_\_\_\_\_, as originally filed  
 pages \_\_\_\_\_, filed with the demand  
 pages \_\_\_\_\_, filed with the letter of \_\_\_\_\_

### 2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language \_\_\_\_\_ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

### 3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

### 4. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages \_\_\_\_\_
- ☐ the claims, Nos. \_\_\_\_\_
- ☐ the drawings, sheet/fig \_\_\_\_\_

### 5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2 (c)).\*\*

\* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

\*\* Any replacement sheet containing such amendments must be referred to under item I and annexed to this report.

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/SE99/01230

## III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application,

☒ claims Nos. 43-52

because:

☒ the said international application, or the said claims Nos. 43-52  
relate to the following subject matter which does not require an international preliminary examination (*specify*):

See PCT Rule 67.1.(iv) .: Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. \_\_\_\_\_  
are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. \_\_\_\_\_ are so inadequately supported  
by the description that no meaningful opinion could be formed.

☐ no international search report has been established for said claims Nos. \_\_\_\_\_

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/SE99/01230

## V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

## 1. Statement

Novelty (N)	Claims	<u>1-42</u>	YES
	Claims		NO
Inventive step (IS)	Claims	<u>1-42</u>	YES
	Claims		NO
Industrial applicability (IA)	Claims	<u>1-42</u>	YES
	Claims		NO

## 2. Citations and explanations (Rule 70.7)

New restricted claims have been filed 29.09.2000. These claims disclose peptides that are based on the sequence constituted of the amino acids 12-40 of human lactoferrin and their use for treatment and/or prevention of infections and inflammations.

During the search the following documents were found:

- A. WO 9806425, A1
- B. JP 07145196
- C. JP 08040925
- D. JP 07274970
- E. JP 09165324
- F. JP 08073499
- G. JP 07309771
- H. US 5 565 425
- I. JP 08143468
- J. WO 9806424
- K. Infection and Immunity, 1998, 66 (6), 2434-2440.
- L. FEBS Letters, 1996, 382, 175-178
- M. US 5 304 633

Document A discloses the use of lactoferrin and lactoferricin in the production of a pharmaceutical composition for treatment of infections, inflammations and tumours. The document shows that lactoferrin has the same use as the claimed peptides.

All of documents B-M disclose peptides that are based on the sequence of lactoferrin.

.../...

**Supplemental Box**

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: V

Document B discloses an antibiotic peptide.

Document C shows lactoferrin-derived peptides that are effective in treating cornea damage.

Document D discloses lactoferrin-derived peptides with antibacterial activity that are closely related to the claimed peptides.

Document E shows lactoferrin-derived peptides with antifungal activity.

Document F shows lactoferrin-derived peptides with immunostimulant activity.

Document G discloses anticancer parenteral compositions that contain lactoferrin-derived peptides.

Document H relates to inhibitors against viral infections.

Document I discloses lactoferrin-derived peptides with antiulcer activity.

Document J relates to lactoferrin-derived peptides that are cancerous metastasis inhibitors for oral administration.

Documents K and L disclose antibacterial peptides.

Document M discloses fragments of lactoferrin with antimicrobial activity.

The known peptides are similar to the claimed peptides but do not have quite the same activity. It is shown in the description that the claimed peptides have a better effect than human lactoferrin.

Thus, claims 1-42 are considered to fulfil the requirement of novelty, inventive step and industrial applicability.

CLAIMS

1. A peptide based on the sequence constituted of the amino acids 12-40 of human lactoferrin counted from the N-terminal end, a modified version thereof, or a  
5 fragment thereof, the sequence of which is SEQ. ID. NO. 1 given in the appended sequence listing wherein X in position 1 is E or none, X in position 2 is A or none, X in position 5 is C or A, X in position 7 is Q or K, X in position 11 is N or D, and X in positions 17-25 are -G-P-P-  
10 V-S-C-I-K-R or none, or functionally equivalent homologues or analogues thereof.

2. A peptide according to claim 1, wherein X in position 1 is E, X in position 2 is A, X in position 5 is C, X in position 7 is Q, X in position 11 is N, and X in  
15 positions 17-25 are -G-P-P-V-S-C-I-K-R, the sequence thus being SEQ. ID. NO. 2 given in appended sequence listing, or functionally equivalent homologues or analogues thereof.

3. A peptide according to claim 2 which is cyclised  
20 through a disulphide bridge, the sequence thus being SEQ. ID. NO. 3 given in the appended sequence listing, or functionally equivalent homologues or analogues thereof.

4. A peptide according to claim 1, wherein X in position 1 is none, X in position 2 is none, X in position  
25 5 is C, X in position 7 is Q, X in position 11 is N, and X in positions 17-25 are is -G-P-P-V-S-C-I-K-R, the sequence thus being SEQ. ID. NO. 4 given in the appended sequence listing, or functionally equivalent homologues or analogues thereof.

30 5. A peptide according to claim 4 which is cyclised through a disulphide bridge, the sequence thus being SEQ. ID. NO. 5 given in the appended sequence listing, or functionally equivalent homologues or analogues thereof.

6. A peptide based on the sequence constituted of  
35 the amino acids 12-40 of human lactoferrin counted from the N-terminal end, a modified version thereof, or a

fragment thereof, the sequence of which is, wherein X in position 1 is none, X in position 2 is none, X in position 5 is A, X in position 7 is K, X in position 11 is D, and X in positions 17-25 are none, the sequence thus being SEQ. ID. NO. 6 given in the appended sequence listing, or functionally equivalent homologues or analogues thereof.

7. A peptide according to claim 6, wherein a lactam bridge is formed between the amino acids K in position 5 and D in position 9, the sequence thus being SEQ. ID. NO. 7 given in the appended sequence listing, or functionally equivalent homologues or analogues thereof.

8. A peptide based on the sequence constituted of the amino acids 12-40 of human lactoferrin counted from the N-terminal end, a modified version thereof, or a fragment thereof, the sequence of which is a fragment of SEQ. ID. NO. 8 given in appended the sequence listing corresponding to SEQ. ID. NO. 31 given in the appended sequence listing, or functionally equivalent homologues or analogues thereof.

9. A peptide based on the sequence constituted of the amino acids 12-40 of human lactoferrin counted from the N-terminal end, a modified version thereof, or a fragment thereof, the sequence of which is a fragment of SEQ. ID. NO. 8 given in appended the sequence listing corresponding to any of SEQ. ID. NO. 31-38 given in the appended sequence listing, or functionally equivalent homologues or analogues thereof.

10. A peptide having one of the sequences SEQ. ID.  
30 NO. 46, 48, 50, 52, 54, 56, 58, 60, 62, 64 or 66, or  
functionally equivalent homologues or analogues thereof.

11. A peptide having one of the sequences SEQ. ID. NO. 50, 52, 54, 56, 60 or 98, or functionally equivalent homologues or analogues thereof.

35           12. A peptide according to claim 10 or 11, wherein  
the N-terminal amino acid is acetylated and/or the C-  
terminal amino acid is amidated.

13. A peptide having one of the sequences SEQ. ID. NO. 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65 or 67, or functionally equivalent homologues or analogues thereof.

14. A peptide having one of the sequences SEQ. ID. NO. 51, 53, 55, 57, 59 61 or 97, or functionally equivalent homologues or analogues thereof.

15. A peptide having a sequence essentially corresponding to one of SEQ. ID. NO. 46-51 and 62-67 but wherein the cysteine has been replaced by an acetamidomethyl-cysteine, or functionally equivalent homologues or analogues thereof.

16. A peptide based on the sequence constituted of the amino acids 12-40 of human lactoferrin counted from the N-terminal end, a modified version thereof, or a fragment thereof, consisting of 12 amino acids, the sequence of which is SEQ. ID. NO. 99, wherein Xaa in position 3 is preferably Gln or Ala, Xaa in position 4 is preferably Trp or Leu, Xaa in position 5 is preferably Gln, Lys, Orn, Ala or Nle, Xaa in position 6 is preferably Arg, Lys or Ala, Xaa in position 7 is preferably Asn, Orn, Ala or Nle, Xaa in position 8 is preferably Met or Leu, and Xaa in position 9 is preferably Arg or Lys.

17. A peptide according to claim 16, the sequence of which is any of SEQ. ID. NO. 68-96 given in the appended sequence listing.

18. A peptide according to claim 17, having SEQ. ID. NO. 70 or SEQ. ID. NO. 74.

19. A peptide according to claim 17, having SEQ. ID. NO. 81 or SEQ. ID. NO. 83.

20. A peptide according to claim 17, having SEQ. ID. NO. 87 or SEQ. ID. NO. 89.

21. A peptide according to claim 17, having SEQ. ID. NO. 91.

22. A medicinal product comprising a peptide according to any of the claims 1-21.

23. A medicinal product according to claim 22 for treatment and/or prevention of infections and/or inflammations.

24. A medicinal product according to claim 23, for  
5 treatment and/or prevention of urinary tract infection.

25. A medicinal product according to claim 23, for treatment and/or prevention of colitis.

26. A medicinal product according to claim 23, for treatment of a candida infection on a mucosal membrane.

10 27. A medicinal product according to any one of the claims 22-27 formulated for oral administration.

28. A medicinal product according to any one of the claims 22-27 formulated for parenteral administration.

15 29. A medicinal product according to claim 28 formulated for topical administration.

30. A medicinal product according to any one of the claims 22-29 formulated for administration on mucosal membranes.

20 31. Food stuff comprising a peptide according to any of the claims 1-21.

32. Food stuff according to claim 31 being an infant formula food.

25 33. Use of a peptide according to any one of the claims 1-21 for the production of a medicinal product for treatment and/or prevention of infections and/or inflammations.

34. Use according to claim 33, wherein the medicinal product is intended for treatment and/or prevention of urinary tract infection.

30 35. Use according to claim 33, wherein the medicinal product is intended for treatment and/or prevention of colitis.

35 36. Use according to claim 33, wherein the medicinal product is intended for treatment of a candida infection on a mucosal membrane.



37. Use according to any one of the claims 33-36, wherein the medicinal product is formulated for oral administration.

38. Use according to any one of the claims 33-36,  
5 wherein the medicinal product is formulated for parenteral administration.

39. Use according to claim 38, wherein the medicinal product is formulated for topical administration.

40. Use according to any one of the claims 33-39,  
10 wherein the medicinal product is formulated for administration on mucosal membranes.

41. Use according to claim 37, wherein the medicinal product constitutes or is included in a food stuff.

42. Use according to claim 41, wherein the food  
15 stuff is an infant formula food.

43. A method for treatment or prevention of infections or inflammations wherein an effective amount of a substance chosen from the group consisting of the peptides having any of the sequences SEQ ID NO 1 - 7,  
20 31 - 38, or 46 - 99, fragments, and functionally equivalent homologues and analogues thereof, is administered to a patient.

44. A method according to claim 43 for treatment and/or prevention of urinary tract infection.

25 45. A method according to claim 43 for treatment and/or prevention of colitis.

46. A method according to claim 43 for treatment and/or prevention of a candida infection on a mucosal membrane.

30 47. A method according to claim 43, wherein the substance is orally administered.

48. A method according to claim 43, wherein the substance is parenterally administered.

35 49. A method according to claim 48, wherein the substance is topically administered.

50. A method according to claim 49, wherein the substance is administered on mucosal membranes.

47

51. A method according to claim 47, wherein the substance is included in a food stuff.

52. A method according to claim 51, wherein the substance is included in an infant formula food.

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07K 14/79, A61K 38/40</b>		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/01730</b>
			<b>(43) International Publication Date:</b> 13 January 2000 (13.01.00)
<b>(21) International Application Number:</b> PCT/SE99/01230 <b>(22) International Filing Date:</b> 6 July 1999 (06.07.99)  <b>(30) Priority Data:</b> 9802441-7 6 July 1998 (06.07.98) SE 9802562-0 17 July 1998 (17.07.98) SE 9804614-7 29 December 1998 (29.12.98) SE  <b>(71) Applicant (for all designated States except US):</b> A+ SCIENCE INVEST AB [SE/SE]; Kungsportsavenyn 31-35, S-400 10 Göteborg (SE).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> <u>HANSON</u> , Lars, Å. [SE/SE]; Västergatan 2, S-411 26 Göteborg (SE). <u>MATTSBY-BALTZER</u> , Inger [SE/SE]; Förtroligheten 23, S-412 70 Göteborg (SE). <u>BALTZER</u> , Lars [SE/SE]; Förtroligheten 23, S-412 70 Göteborg (SE). <u>DOLPHIN</u> , Gunnar, T. [SE/SE]; Skytteskogsgatan 14, S-414 76 Göteborg (SE).  <b>(74) Agent:</b> AWAPATENT AB; P.O. Box 11394, S-404 28 Göteborg (SE).			<b>(81) Designated States:</b> AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> PEPTIDES BASED ON THE SEQUENCE OF HUMAN LACTOFERRIN AND THEIR USE			
<b>(57) Abstract</b>  The invention relates to new peptides formed of at least seven subsequent amino acids of the amino acids in position 12-40, counted from the N-terminal end, in the sequence constituting human lactoferrin, and preferably modifications thereof. The invention also relates to medicinal products comprising such peptides, especially intended for treatment and prevention of infections, inflammations and tumours. Furthermore, the invention relates to food stuff, e.g. infant formula food, comprising the above mentioned peptides.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## PEPTIDES BASED ON THE SEQUENCE OF HUMAN LACTOFERRIN AND THEIR USE

Field of the invention

The present invention relates to new peptides and to use thereof, in particular for treatment and/or prevention of infections, inflammations and/or tumours.

5

Background art

It has for a long time been known that human milk in several ways is anti-inflammatory due to the fact that it is poor in initiators and mediators of inflammation but  
10 rich in anti-inflammatory agents (see e.g. Goldman A. S., et al., Anti-inflammatory properties of human milk, Acta Paediatr. Scand. 75:689-695, 1986). Human milk also contains several soluble anti-infective components, such as lactoferrin (see e.g. Hanson L. Å., et al., Protective  
15 factors in milk and the development of the immune system, Pediatrics 75:172-176, 1983).

Lactoferrin is a single chain metalbinding glycoprotein with a molecular weight of 77 kd. It has been found that the structural domain of lactoferrin responsible for  
20 the bactericidal properties is a pepsin-cleaved fragment called lactoferricin (see e.g. Bellamy W., et al., Identification of the bactericidal domain of lactoferrin, Biochim. Biophys. Acta 1121:130-136, 1992, and Bellamy W., et al., Antibacterial spectrum of lactoferricin B, a  
25 potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin, J. Appl. Bact. 73:472-479, 1992).

Lactoferrin receptors are found on many types of cells including monocytes and macrophages, lectin-  
30 stimulated human peripheral blood lymphocytes, brush-border cells, and tumour cell lines.

Several patent publications describe the possible use of lactoferrin for treatment of infections or inflammations. In WO 98/06425, e.g., it is disclosed that lac-

toferrin and lactoferricin can be used for treatment and prevention of infections, inflammations and tumours.

EP-A-0 629 347 describes an antimicrobial agent containing (A) lactoferrin hydrolysate and/or one or more of  
5 antimicrobial peptides derived from lactoferrins, and (B) one or more compounds selected from the group consisting of metal-chelating protein, tocopherol, cyclodextrin, glycerine-fatty acid ester, alcohol, EDTA or a salt thereof, ascorbic acid or a salt thereof, citric acid or  
10 a salt thereof, polyphosphoric acid or a salt thereof, chitosan, cysteine, and cholic acid as the effective components thereof. This antimicrobial agent is intended for treatment of products, and especially for safely treating e.g. food and medicines. The agent according to this publication is thus a new preservative. In the publication  
15 several peptide sequences are given and some of them resemble the peptides according to the invention, although there are several important differences described further below.

20 Even though native human lactoferrin and lactoferricin have been shown to have desired anti-inflammatory, anti-infectious and anti-tumoural properties they cannot be used clinically on a broad basis since they are very expensive substances due to high production costs.

25

#### Summary of the invention

The object of the present invention is to provide new peptides which can be used for the same purposes as lactoferrin and/or lactoferricin and which will have the  
30 same, or better, effects although being much cheaper to produce.

The aim of the studies leading to the present invention was to design new peptides which could be taken up from the intestines. It has been shown that humans in  
35 their brush border membrane have receptors which can bind to human lactoferrin (see e.g. Lönnerdal B., Lactoferrin receptors in intestinal brush border membranes, Adv. Exp.

Med. Biol., 1994, 357:171-175). It has also been shown that bovine lactoferrin does not bind to these receptors. The new peptides should therefore resemble human lactoferrin or human lactoferricin but they should also be easier and especially cheaper to produce. Furthermore, they should be essentially as efficient as, or preferably more efficient than, human lactoferrin or human lactoferricin in treatment and prevention of infections, inflammations and tumours.

10 It was found that peptides formed of the sequences constituted of all or some of the amino acids 12-40 of human lactoferrin counted from the N-terminal end, and preferably modified versions thereof described further below, have the desired properties.

15 According to a first embodiment of the invention, it is shown that the peptides formed of the sequences constituted of amino acids 16-40 and amino acids 18-40 from the N-terminal end of human lactoferrin, with some alterations described further below, have the desired properties. Also sequences with only 14 residues, roughly corresponding to residues 18-31 of human lactoferrin wherein C-20 is replaced by A, Q-22 is replaced by K, and N-26 is replaced by D, were found to have the same, and even better, properties.

20 According to a second embodiment of the invention, it is shown that the peptide formed of the amino acids in positions 12-31, counted from the N-terminal end, in the sequence constituting human lactoferrin, as well as modifications thereof, have the desired properties. Also fragments of this sequence consisting of at least 7 amino acids are shown to have the same, and even better, properties.

25 According to a third embodiment of the invention it is shown that peptides consisting of 11-17 amino acids corresponding to the sequences that begin with one of the amino acids in positions 15-21 and end with the amino acid in position 31, counted from the N-terminal end, in

the sequence constituting human lactoferrin, as well as modifications thereof.

According to a forth embodiment of the invention it is shown that modified peptides consisting of 12 aminoac-  
5 ids based on the sequence consisting of the amino acids in positions 20-31 in human lactoferrin, counted from the N-terminal end, give even better results for the purposes of the present invention.

A plausible mechanism for the uptake of these new  
10 peptides in the human body is that the peptides are taken up in the intestine through binding to the above mentioned specific lactoferrin receptors and are then transported through the circulation. However, the invention is in no way limited to this mechanism.

15 Thus, the present invention relates to new peptides with the sequences given in the appended sequence listing, and to functionally equivalent homologues or analogues thereof.

Furthermore, the invention relates to medicinal  
20 products and to food stuff, especially infant formula food, comprising said peptides.

The invention also relates to use of said peptides for the production of medicinal products for treatment and prevention of infections, inflammations and tumours.

25 The peptides according to the invention are fungicidal and bactericidal, and can thus be used for other applications when substances with such properties are desired. They may for example be used as preservatives.

The characterising features of the invention will be  
30 evident from the following description and the appended claims.

#### Detailed description of the invention

Thus, the present invention relates to peptides comprising - amino acid based on a fragment of the protein  
35 human lactoferrin (hLF). The fragment of hLF that are



used as a basis for the invention is constituted by the amino acids in positions 12-40, the sequence of which is:

V-S-Q-P-E-A-T-K-C-F-Q-W-Q-R-N-M-R-K-V-R-G-P-P-V-S-C-I-K-R

5

(SEQ. ID. NO. 100)

In the description single-letter symbols are used to denote the amino acids, while three-letter symbols are used in the appended sequence listing. These symbols, which are well known to man skilled in the art, have the following meaning: A = Ala = alanine, C = Cys = cysteine, D = Asp = aspartic acid, E = Glu = glutamic acid, F = Phe = phenylalanine, G = Gly = glycine, I = Ile = isoleucine, K = Lys = lysine, M = Met = methionine, N = Asn = asparagine, P = Pro = proline, Q = Gln = glutamine, R = Arg = arginine, S = Ser = serine, T = Thr = threonine, V = Val = valine, W = Trp = tryptophan and X = Xaa = a variable amino acid. Ac and NH<sub>2</sub> in some of the sequences denote an acetyl (CH<sub>3</sub>CO-) group and an amino group, respectively, that have been used to modify the amino and the carboxy terminals of the peptides.

The peptides according to the invention may have either of a linear or a cyclic form, which is further explained below.

All the sequences mentioned herein with SEQ. ID. NO. 1-99 are given in the appended sequence listing.

The first embodiment of the invention relates to peptides the sequence of which is:

Ac-X-X-T-K-X-F-X-W-Q-R-X-M-R-K-V-R-X-X-X-X-X-X-X-X-NH<sub>2</sub>

30

(SEQ ID. NO. 1)

wherein X in position 1 is either E or no amino acid, X in position 2 is either A or no amino acid, X in position 5 is either C or A, X in position 7 is either Q or K, X in position 11 is either N or D, and X in positions 17-25 are either no amino acids at all or -G-P-P-V-S-C-I-K-R.

35

The sequences for the peptides according to the first embodiment of the inventions are SEQ. ID. NO.1-7 in the appended sequence listing.

In a preferred version of the first embodiment of the invention X in position 1 is E, X in position 2 is A, X in position 5 is C, X in position 7 is Q, X in position 11 is N, and X in positions 17-25 are -G-P-P-V-S-C-I-K-R, which gives a peptide the sequence of which is SEQ. ID. NO. 2. The linear form is obtained through protection of the cysteine side chains by acetamidomethyl groups  $\text{CH}_3\text{CONHCH}_2-$ .

Another preferred version of the first embodiment of the invention is a cyclic form of SEQ. ID. NO. 2, obtained by the creation of a disulphide bridge between the two cysteines in positions 5 and 22, resulting in the cyclic peptide the sequence of which is SEQ. ID. NO. 3. The creation of the disulphide bridge has to be performed in a controlled way in order to avoid formation of polymers.

Another preferred version of the first embodiment of the invention is a somewhat shorter peptide wherein X in position 1 in SEQ. ID. NO. 1 is none, X in position 2 is none, X in position 5 is C, X in position 7 is Q, X in position 11 is N, and X in positions 17-25 are -G-P-P-V-S-C-I-K-R, resulting in a peptide the sequence of which is SEQ. ID. NO. 4.

Yet another preferred version of the first embodiment of the invention is a cyclic form of SEQ. ID. NO. 4 obtained by the creation of a disulphide bridge in the same way as for SEQ. ID. NO. 3, resulting in SEQ. ID. NO. 5.

An even more preferred version of this first embodiment of the invention is shorter peptide in which X in position 1 is none, X in position 2 is none, X in position 5 is A, X in position 7 is K, X<sub>5</sub> D, and X in positions 17-25 are none, resulting in SEQ. ID. NO. 6.

This peptide may also be modified so that the residues K in position 5 in SEQ. ID. NO. 6 and D in position

9 are linked by the formation of a lactam between the side chains of the residues, thus forming a loop. The sequence of this peptide is SEQ. ID. NO. 7. The lactam formation in this peptide between amino acid chains that are  
5 four residues apart in the sequence forces the peptide to adopt a three-dimensional structure that resembles that of the fragment 18-31 of naturally occurring human lactoferrin and is designed to bind better to the receptor. This peptide with SEQ. ID. NO. 7 is the most preferred  
10 peptide according to the first embodiment of the invention.

One advantage of the peptides with SEQ. ID. NO. 6 and SEQ. ID. NO. 7 compared to the other peptides according to the first embodiment of the invention is that they  
15 are easier to synthesise and also cheaper per gram since they are shorter.

In all those seven peptides the amino and carboxy terminal ends have been capped, i.e. the free  $\text{NH}_2$  group at the amino terminal end have been reacted with acetylimidazole to form the amide  $\text{CH}_3\text{CONH-}$  or  $\text{AcNH-}$  and the  
20 free  $\text{COOH}$  at the carboxy terminal end has been transformed into  $\text{CONH}_2$ .

As evident from the sequences above all seven peptides according to the first embodiment of the invention  
25 comprise the residues K and R at the carboxy terminal ends. These residues are positively charged under physiological conditions and are capable of strong and specific interactions with receptors. They are therefore an important part of the peptides according to the invention.  
30 Also the T residue at the amino terminal end of all of the peptides according to the invention is capable of playing an important part in receptor binding.

The second embodiment of the invention relates to the peptide the sequence of which is:

35

V-S-Q-P-E-A-T-K-C-F-Q-W-Q-R-N-M-R-K-V-R

(SEQ. ID. NO. 8)

and fragments thereof consisting of at least 7 amino acids. The sequences for the peptides according to the second embodiment of the inventions are SEQ. ID. NO.8-42 in the appended sequence listing.

The peptides according to this second embodiment of the invention contains at least 7 amino acids. Shorter peptides do not have the desired effects.

A preferred group of peptides according to the second embodiment of the invention are the peptides with SEQ. ID. NO. 9-22 given in the appended sequence listing. The advantage of these peptides, consisting of only seven amino acids each, is that they are relatively short which means that they are cheaper and more easy to produce than the longer peptides according to the invention.

Another preferred group of peptides according to this second embodiment of the invention are the peptides with SEQ. ID. NO. 13 and SEQ. ID. NO. 23-31 in the appended sequence listing, corresponding to modified sequences obtained from the amino acid in position 16 to the amino acid in position 22-31 of human lactoferrin, counted from the N-terminal end.

Yet another preferred group of peptides according to this embodiment are the peptides with SEQ. ID. NO. 22 and SEQ. ID. NO. 31-42 in the appended sequence listing, corresponding to modified sequences obtained from the amino acid in position 13-25 to the amino acid in position 31 of human lactoferrin, counted from the N-terminal end.

The advantage of the peptides according to the second embodiment of the invention is that they form the part of the lactoferricin fragment of the human lactoferrin protein, or a modified version thereof, which the inventors have found to be active with regards to the invention.

The third embodiment of the invention relates to peptides consisting of 11-17 amino acids, comprising the sequence:

F-X-W-X-R-X-M-R-K-X-R

(SEQ. ID. NO. 43)

5 or functionally equivalent homologues or analogues thereof. The sequences for the peptides according to the third embodiment of the inventions are SEQ. ID. NO.43-67 and SEQ. ID. NO. 97 in the appended sequence listing.

10 In this sequence, the amino acids denoted by X or Xaa are preferably, independently of each other, glutamine (Q or Gln), lysine (K or Lys), aspartic acid (D or Asp), asparagine (N or Asn), or valine (V or Val).

A preferred group of peptides according to the second embodiment of the invention consists of 14 amino acids. Those peptides correspond essentially to the sequence formed by the amino acids in positions 18-31, counted from the N-terminal end, in the sequence constituting human lactoferrin, wherein some amino acids have been modified. The peptides in this group have the sequences SEQ. ID. NO. 6, 7, 50-61 and 98.

The peptide according to this embodiment that mostly corresponds to this part of human lactoferrin is the peptide with SEQ. ID. NO. 50 given in the appended sequence listing. The capped version of this sequence has SEQ. ID. NO. 51.

The amino acid in position 3 in this sequence, i.e. a cysteine (C or Cys) may be replaced by an alanine (A or Ala) or a lysine, the amino acid in position 5, a glutamine, may be replaced by a lysine, the amino acid in position 9, an asparagine, may be replaced by an aspartic acid or a lysine, and the amino acid in position 13, a valine, may be replaced by an aspartic acid.

When the peptide according to this embodiment comprises a cysteine, as the peptides with SEQ. ID. NO. 46-51 and 62-67, it may be advantageous to replace this cysteine by an acetamidomethyl-cysteine in order to avoid that the peptide forms a disulphide bridge with another

peptide comprising a cysteine. However, the amino acids glutamine and valine may then not be replaced as described above.

5 A major advantage of the peptides according to this embodiment is that they form the part, or a modified version of it, of the lactoferricin fragment of the human lactoferrin protein which the inventors have found to be active with regards to the invention.

10 An other advantage of the peptides according to this embodiment is that they are relatively short which means that they are cheaper and easier to produce than longer peptides, such as lactoferrin itself.

The fourth embodiment of the invention relates to peptides consisting of 12 aminoacids. These peptides are  
15 based on a modification of the sequence consisting of the amino acids in positions 20-31 in human lactoferrin, counted from the N-terminal end, corresponding to SEQ. ID. NO. 46. The sequences for the peptides according to the third embodiment of the inventions are SEQ. ID. NO.  
20 68-99 in the appended sequence listing. In the general sequence, SEQ. ID. NO. 99, Xaa in position 3 is preferably Gln or Ala, Xaa in position 4 is preferably Trp or Leu, Xaa in position 5 is preferably Gln, Lys, Orn, Ala or Nle, Xaa in position 6 is preferably Arg, Lys or Ala,  
25 Xaa in position 7 is preferably Asn, Orn, Ala, or Nle, Xaa in position 8 is preferably Met or Leu, and Xaa in position 9 is preferably Arg or Lys. In some cases it may be advantageous to let this sequence be proceeded by the sequence Thr-Lys or the longer sequence Glu-Ala-Thr-Lys.

30 Preferred variants of the fourth embodiment of the invention are SEQ. ID. NO. 70 and SEQ. ID. NO. 74 wherein the amino acid in position 3 and position 7, respectively, in SEQ. ID. NO. 46 has been replaced by an alanine, SEQ. ID. NO. 81 and SEQ. ID. NO. 83 wherein the  
35 amino acid in position 6 and position 9, respectively, in SEQ. ID. NO. 46 has been replaced by a lysine, and SEQ. ID. NO. 87 and SEQ. ID. NO. 89 wherein the amino acid in

position 5 and position 7, respectively, in SEQ. ID. NO. 46 has been replaced by an ornithine. It is also possible and in some cases preferable, to use capped versions of these sequences according to the invention.

5       The peptides according to the invention may be either of natural origin, e.g. derived from human lactoferrin, or synthetically produced.

          The peptides according to the invention are sometimes "capped", so that the amino and the carboxy terminals of the peptides are turned into amides, as described above. The advantage of the capped versions, i.e. the sequences in which the amino and carboxy terminal ends have been reacted with acetylimidazole to form the amide  $\text{CH}_3\text{CONH-}$  or  $\text{AcNH-}$  and the free  $\text{COOH}$  at the carboxy terminal end has been transformed into  $\text{CONH}_2$ , is that these  
10       peptides are neutral and uncharged and thus has drastically changed electrostatic properties. Assuming that the receptors bind the corresponding sequences of human lactoferrin where there are no N- and C terminal charges,  
15       the capped peptides should bind better as they in this respect resemble the native protein more than uncapped peptides. Under physiological conditions at a pH of approximately 7, free amino and carboxy terminals would be ionised and the peptide would thus carry a positive and a  
20       negative charge.  
25       

          In some cases only the capped form of a sequence has been given in the appended sequence listing. However, it is also possible, according to the invention, to use the non-capped forms.

30       When the peptide according to this embodiment comprises a lysine separated from an aspartic acid or a glutamic acid by three amino acids the lysine and the aspartic acid or the glutamic acid, respectively, may form a lactam, as in SEQ. ID. NO. 54, wherein a lactam is formed  
35       between a lysine in position 5 and an aspartic acid in position 9, or as in SEQ. ID. NO. 55 wherein a lactam is formed between a lysine in position 5 and a glutamic acid

in position 9. It is also possible to obtain a dilactam, as e.g. in SEQ. ID. NO. 60 and SEQ. ID. NO. 61, wherein a lactam is formed between a lysine in position 3 and an aspartic acid in position 7 and another lactam is formed  
5 between a lysine in position 9 and an aspartic acid in position 13. The lactam formation forces the peptide to adopt a three-dimensional structure that resembles that of the corresponding fragment of human lactoferrin and this may accomplish better binding of the peptide to the  
10 lactoferrin receptor.

Apart from the above specified peptides it is also possible to use functionally equivalent homologues or analogues thereof, including those that mimic the three-dimensional structure of the corresponding segment in human lactoferrin due to the introduction of structural  
15 constraints such as lactam bridges or other chemical constraints.

The peptides according to the invention are suitable for treatment and/or prevention of infections, inflammations and/or tumours. The term "treatment" used herein  
20 refers to curing, reversing, attenuating, alleviating, minimising, suppressing or halting the deleterious effects of a disease state, disease progression or other abnormal condition, and the term "prevention" used herein  
25 refers to minimising, reducing or suppressing the risk of developing a disease state or progression or other abnormal or deleterious conditions.

The infections treatable with the peptides or medicinal products according to the invention include infections caused by all kinds of pathogens, such as bacteria, viruses, fungi, etc.  
30

It is also possible to treat different types of inflammations. Inflammation is a complex phenomenon marked i.a. by abnormal "redness" and swelling of tissues and organs, pain and heat in affected areas, capillary dilation, leucocyte infiltration, etc. Inflammation is primarily caused by exposure to bacterial and other noxious  
35



agents and physical injury. Inflammation has many forms and is mediated by a variety of different cytokines and other chemical signals. These mediators of inflammation include tumour necrosis factor- $\alpha$  (TNF- $\alpha$ ), interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8), and various colony-stimulating factors (CSFs).

As stated above, the peptides according to the invention are also suitable for treatment of tumours.

The peptides according to the invention may either be used as they are or be included in a medicinal product or a pharmaceutical preparation. The medicinal product or a pharmaceutical preparation according to the invention may also comprise substances used to facilitate the production of the pharmaceutical preparation or the administration of the preparations. Such substances are well known to people skilled in the art and may for example be pharmaceutically acceptable adjuvants, carriers and preservatives.

The peptides or medicinal products according to the invention can be administered to a patient either systemically or locally. The term "patient" used herein relates to any person at risk for or suffering from a disease state, disease progression or other abnormal or deleterious condition.

The systemic administration is suitable e.g. for treatment of urinary tract infection, colitis and tumours. The systemic administration can be undertaken by oral, nasal, intravenous, intraartery, intracavitary, intramuscular, subcutaneous, transdermal, suppositories (including rectal) or other routes known to those of skill in the art. Oral administration is preferred.

The local administration is suitable e.g. for treatment of skin infections, all infections and inflammations in mucosal membranes etc. The local administration can be undertaken by topical, oral, nasal, vaginal or oropharyngeal route. For treatment of local infections or inflammations in the skin or mucosal membranes the peptides or

medicinal products according to the invention may e.g. be included in a gel, a cream, an ointment, or a paste.

In the method according to the invention an effective amount of a peptide according to the invention is administered to a patient. The term "effective amount" used herein relates an amount sufficient to treat or prevent a disease state, disease progression or other abnormal or deleterious conditions.

The peptides or medicinal products and methods according to the invention are particularly well suited for treatment and/or prevention of urinary tract infection and colitis, but several other inflammatory and infectious diseases are also treatable according to the present invention, such as inflammatory bowel diseases, rheumatoid arthritis, conditions caused by the virus HIV-1, conditions caused by the virus CMV, and conditions caused by the fungi *Candida albicans*, *Candida krusei* and *Cryptococcus neoformans*. This listing is in no way limiting the scope of the invention.

The peptides, medicinal products and methods according to the invention are also well suited for preventive medical care by reducing the risk of developing urinary tract infection or other inflammatory or infectious diseases in patients with an increased risk of attracting such complications.

The peptides, medicinal products and methods according to the invention may either be used alone, in combination with each other or in combination with conventional therapy.

According to the present invention it is also possible to include the peptides, in an effective amount, in any kind of food or beverage intended to reduce infections and/or inflammations in patients running an increased risk of such conditions due to an underlying disease, a low birth weight or a medical treatment. For example, it is possible to include the peptides, in an effective amount, in an infant formula food intended to in-

hibit harmful effects of bacteria, such as weight loss caused by inflammation induced by bacteria, viruses or fungi in infants. When the peptides according to the invention is to be used in food stuffs, e.g. for nutritional purposes, it is especially preferred to use peptides of natural origin.

Since the peptides according to the invention have antimicrobial effects they can also be used as preservatives in different food stuffs and medicinal products such as gels, creams, ointments, pastes, solutions, emulsions etc.

The invention will now be further explained in the following examples. These examples are only intended to illustrate the invention and should in no way be considered to limit the scope of the invention.

#### Brief description of the drawings

In the examples below, reference is made to the appended drawings on which:

Fig. 1 shows the number of bacteria (CFU) present in kidney in mice with urinary tract infection treated with two peptides according to the invention, peptide 3 and peptide 4, with human lactoferrin, hLF, and with water, respectively.

Fig. 2 illustrates the concentrations needed of peptide 3 in linear and cyclic form, peptide 4 in linear and cyclic form, and peptide 7 compared to a reference peptide in linear and cyclic form for killing of 99% of *C. albicans* at different pH.

Fig. 3 shows the number of *C. albicans* (CFU) present in stomach in mice, which were orally treated with two peptides according to the invention, peptide 3 and peptide 4, with human lactoferrin (hLF) and with water (Control), respectively, after intragastrical administration of *C. albicans*.

Fig. 4 illustrates the result of peroral treatment of mice with experimental colitis with peptide 3 and pep-

5     tide 4, and with hLF compared to treatment with water (control). Fig. 4 A shows the occurrence of occult blood in faeces, Fig. 4 B shows the amount of IL-1 $\beta$  in serum, Fig. 4 C shows the occurrence of rectal bleeding, and Fig. 4 D shows the colon length.

     Fig. 5 A illustrates the number of CD8 positive cells in tissue sections of distal colon from the mice treated according to Fig. 4.

10     Fig. 5 B illustrates the expression of MHC class II in tissue sections of distal colon from the mice treated according to Fig. 4.

#### Examples

     In the examples below peptide 2 denotes the peptide according to the invention with SEQ. ID. NO. 2, peptide 3 denotes the peptide according to the invention with SEQ. ID. NO. 3, etc.

     Morinaga 10, Morinaga 11, Morinaga 12, Morinaga 13, Morinaga 24 and Morinaga 25 denotes the peptides described in EP-A-0 629 347; Morinaga 10 is F-Q-W-Q-R-N (sequence No. 10 in EP-A-0 629 347), Morinaga 11 is F-Q-W-Q-R (sequence No. 11 in EP-A-0 629 347), Morinaga 12 is Q-W-Q-R (sequence No. 12 in EP-A-0 629 347), Morinaga 13 is W-Q-R (sequence No. 13 in EP-A-0 629 347), Morinaga 24 is the cyclic peptide with sequence K-C-F-Q-W-Q-R-N-M-R-K-V-R-G-P-P-V-S-C-I (sequence No. 24 in EP-A-0 629 347), and Morinaga 25 is K-C-F-Q-W-Q-R-N-M-R-K-V-R-G-P-P-V-S-C-I (sequence No. 25 in EP-A-0 629 347).

     hLF denotes human lactoferrin.

30     In the examples, the minimal microbicidal concentrations (MMC) and minimal inhibitory concentrations (MIC) were determined as follows, unless otherwise specified in the examples. Bacterial or fungal strains were cultured in BHI medium over night at 37°C. A volume of the culture was transferred to a new tube with BHI and incubated for two more hours. Thereafter the cells were spun down and the pellet was suspended in BHI medium diluted 1/100 (1%

BHI). The concentration of bacterial or fungal cells was spectrophotometrically determined at 650 nm. The microbial concentrations were also determined by viable counts. Peptides serially diluted in 1% BHI by twofold or  
5 tenfold steps were added in triplicate to the wells of a microtiterplate (200 µl per well). The bacterial or fungal cell solutions were added in 10 µl volumes to give a final concentration of approximately  $1-5 \times 10^5$  cells per ml in the well. The microplate was incubated at 37°C in a  
10 humid chamber for two hours. Thereafter 5 µl was taken from each well and added as a drop onto a blood agar plate and incubated over night at 37°C. The microplate was incubated for another 20 hours at 37°C and thereafter analysed spectrophotometrically at 650 nm in a microplate  
15 reader (Emax, Molecular Devices, USA). The concentration of peptide causing a 99% reduction of the inoculum after 2 hours of incubation was defined as the MMC<sub>99%</sub>. The MIC value was defined as the concentration giving no increase in the absorbance value above the background level after  
20 20 hours of incubation.

#### Example 1

This example illustrates solid phase synthesis of peptide 2, peptide 3, peptide 4 and peptide 5 according  
25 to the invention, and also of the peptides Morinaga 24 and Morinaga 25 used in the examples further below.

The syntheses were performed by Fmoc continuous flow strategy on a Biosearch Pioneer automated peptide synthesiser. The peptides were synthesised on a 0.1-0.2 mmol  
30 scale with the resins PAC-PEG-PS, 0.21 mmol/g for the peptide acids and Fmoc-PAL-PEG-PS, 0.20 mmol/g for the peptide amides.

The side chains of the peptides according to the invention were protected by piperidine-stable tert-butyl  
35 (for serine and threonine), tert-butyl ester (for glutamic acid), tert-butyloxycarbonyl (for lysine and tryptophan), triphenylmethyl (for asparagine, cysteine, glu-

tamine and histidine), acetamidomethyl (for cysteine), and 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulphonyl (for arginine) groups.

For the peptides Morinaga 24 and Morinaga 25, attachment of isoleucine to the PAC-PEG-PS resin was performed using the isoleucine symmetrical anhydride. The resin (1 g, 0.21 mmol) was allowed to swell in 3 ml dimethyl formamide (DMF). Fmoc-I (10 eq, 2.1 mmol) was dissolved in 5 ml dichloromethane (DMC) and 5 drops of DMF. Diisopropyl carbodiimide (DIPCDI) (5 eq, 1.05 mmol) was added to the amino acid solution after which it was left to stand for 20 min at 0°C. The DCM was removed under reduced pressure and the remaining oil was dissolved in DMF and added to the resin. Dimethylaminopyridine (DMAP) (1 eq) was added to the resin and the slurry was allowed to stand at room temperature with occasional swirling for 1 hour. After washing with DCM the resin was ready for peptide synthesis.

Removal of the  $\alpha$ -amino protecting group (Fmoc) was performed with 20% piperidine in DMF for 7 min. All couplings proceeded in DMF, using 4 times excess of activated amino acid over peptide and 4 eq of benzotriazolyl tetramethyluronium tetrafluoroborate (TBTU):diisopropyl ethylamine (DIPEA) (1:2, mol/mol). A six fold excess of hydroxybenzotriazole (HOBt) was added to the couplings of the cysteine residues (acetamidomethyl and triphenylmethyl).

Peptide 2, peptide 3, peptide 4, and peptide 5 were acylated at the amino terminus using a 0.3 M solution of acetic anhydride in DMF.

Final deprotection and cleavage of the peptide from the resin was performed for 2 hours at room temperature using a mixture of 9.25 ml trifluoro acetic acid (TFA), 250  $\mu$ l water, 250  $\mu$ l ethanedithiol and 250  $\mu$ l triisopropylsilan per g of peptide resin. The resin was removed by filtration. The peptide was precipitated by use of cold diethylether, centrifuged and resuspended in fresh dieth-

ylether two more times to extract the scavengers and TFA. The peptides were dissolved in water and lyophilised.

The cyclisation of the disulphide bonded peptides, peptide 3 and peptide 5, were performed on unpurified material. Approximately 200 mg of peptide was dissolved in 1 l of degassed water. Ammonium hydrogen carbonate was added until the pH was in the range of 6-7 and the mixture was left with stirring and air contact for about 1 day, and was finally lyophilised.

The peptides were purified by reversed-phase high-pressure liquid chromatography eluting with isocratic mixtures of isopropanol (12-16% IPA) and 0.1% TFA. Two different columns were used, Microsorb, C-8 41.4x250 mm, 8  $\mu$ m (column A), and Hichrom, C-8 25x250 mm, 7  $\mu$ m (column B). The peptides eluted as broad peaks with the retention times (R) given in table 1 below. The identification was done by ES-MS. MW in the table denotes the molecular weight.

## 20 Example 2

This example illustrates solid phase synthesis of peptide 6 and peptide 7 according to the invention.

The syntheses were performed as described in example 1 with the following modifications of the synthetic procedure. The side chains of the lactam forming amino acids K in position 5 and D in position 9 were protected by 1(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl (Dde) and 4-{N-[1(4,4-dimethyl-2,6-dioxocyclohexylidene)-3-methylbutyl]-amino}benzyl ester (ODmab), respectively.

After the synthesis of the capped sequence was completed, the Dde and ODmab groups were removed by 2% hydrazine (v/v) in DMF for 10 min. The resin was washed with DMF, 1M DIPEA in DMF and finally by DMF.

In the case of peptide 7 lactam formation between the side chains was allowed to proceed for 8 hours after the addition of a four fold excess of azabenzotriazolyl tetramethyluronium hexafluorophosphate (HATU):DIEPEA, 1:2

in DMF. The resin was washed with the following solvents/solutions: DMF, 20% piperidine in DMF, methanol and DCM. The resin was dried under vacuum, and the peptide was cleaved from the resin as described above.

5        Peptide 7 eluted as a broad peak with the retention times (R) given in table 1 below.

Table 1

Peptide	Column	% IPA	Flow (ml/min)	R (min)	MW (found/calc.)
Peptide 2	B	14	15	11	3201/3204.7
Peptide 3	A	13	80	16	3057.1/3060.7
Peptide 4	A	14	80	12	3002.4/3004.0
Peptide 5	B	14	15	10	not determined
Peptide 7	B	12	18	12	not determined
Morinaga 24	B	16	15	20	2575/2576.0
Morinaga 25	B	16	15	18	3430/3432.0

10

Example 3

In this example the bactericidal activity of the peptides according to the invention was tested and compared to the bactericidal activity of human lactoferrin.

15        Human lactoferrin (hLF), peptide 3, and peptide 4, respectively, were incubated with two different strains of E. coli, E. coli O14 (experiment I) and O6K5 (experiment II), in diluted growth medium (1/100 BHI - brain heart infusion) for 2 hours. The peptides were also incubated with E. coli O14 in 0.05 mM KCl (pH 7) without any growth medium (experiment III). Different concentrations of the peptides were tested.

20        After the incubation, samples were taken for bacterial plating. Serial dilutions of five- and fourfold steps were used in experiments I and II, respectively, and of twofold steps in experiment III.

25



The concentrations of the different peptides required for killing 100% (experiments I and II) or 90% (experiment III) of the bacteria are given in table 2.

5

Table 2

Exp.	Agent	Concentration of agent for 100%/90% killing ( $\mu\text{g/ml}$ )
I	hLF	400
I	peptide 3	4.4
I	peptide 4	4.4
II	hLF	2000
II	peptide 4	$\leq 7.8$
III	hLF	$> 4000$
III	peptide 3	12.5
III	peptide 4	3.2

From table 2 it is evident that the peptides according to the invention were much more efficient as bactericidal agents than human lactoferrin.

Example 4

In this example the fungicidal activity of the peptides according to the invention was tested and compared to the fungicidal activity of human lactoferrin. Different concentrations of hLF, peptide 3 and peptide 4 were incubated with different strains of *Candida albicans* and *Candida krusei* during 1-2 hours at 37°C in 0.05 mM KCl at pH 7.0 at two different occasions - experiment I and II, respectively. After incubation samples were taken for plating on Saboroud plates. The concentrations of the different peptides required for killing 99% of the fungi are given in table 3.

Table 3

Exp.	Candida strain	Concentration of agent for 99% killing ( $\mu\text{g/ml}$ )			ratio hLF/	
		hLF	peptide 3	peptide 4	/pep. 3	/pep. 4
I	C. albicans ATCC 64549	> 50	0.6	1.25	> 83	> 40
I	C. albicans CCUG 90028	> 50	0.6	1.25	> 83	> 40
I	C. krusei CCUG 35849	12.5	0.6	1.25	21	10
I	C. krusei CCUG 969	25	1.25	2.5	20	10
II	C. albicans ATCC 64549	> 200	1.5	1.5	> 133	> 133
II	C. albicans CCUG 599	> 200	1.5	1.5	> 133	> 133
II	C. albicans CCUG 1759	> 200	1.5	1.5	> 133	> 133

The results in table 3 show that the peptides according to the invention were much more efficient fungicidal agents than human lactoferrin.

#### Example 5

In this example an in vitro test was performed to study the anti-inflammatory activity of the peptides according to the invention. More precisely, the inhibitory effect of the peptides according to the invention on the LPS-induced IL-6 response in a monocytic cell line (THP-1) was studied and compared to the effect of human lactoferrin by use of the method described by I. Mattsby-Baltzer et al., *Pediatr. Res.* 40:257-262, 1996. The IL-6 response in the THP-1 cells was induced by addition of LPS. hLF, peptide 3 and peptide 4, respectively, were added 30 minutes after LPS. A significant inhibition was

obtained with peptide 4, as shown in table 3 below. The inhibitory activity of peptide 3 was similar to the inhibitory activity of human lactoferrin.

5

Table 4

Agent	% inhibition of LPS response
hLF	15
peptide 3	17
peptide 4	39

Example 6

Peptide 3 and peptide 4 according to the invention were also tested in an in vivo study to show their effect on urinary tract infection.

E. coli O6K5 was instilled into the urinary bladder of mice. 30 minutes after instillation the different agents specified in table 5 were administered orally in an amount of 500 µg per mouse and 24 hours after instillation the number of bacteria (CFU) present in bladder and in kidney was determined. The result is shown in table 5.

The control group consisted of 10 animals in experiment I and of 23 animals in experiment II. The animals in the control groups were given tap water instead of peptide or hLF.

Table 5

Exp	Agent	Mouse strain	No. of animals	Statistical comparison* of treatment group with control group of the number of bacteria, CFU, present in kidney
I	peptide 4	CH/HeN	11	p = 0.0137
II	peptide 3	C3H/Tif	23	p = 0.0574
II	peptide 4	C3H/Tif	23	p = 0.0102
II	hLF	C3H/Tif	23	p = 0.006

\* Mann-Whitney

5       The results from experiment II are also illustrated in figure 1.

Thus, the peptides according to the invention are capable of reducing the number of the bacteria in kidney.

#### 10   Example 7

In this example an in vitro test was performed to compare the bactericidal and fungicidal activity of the peptides according to the invention with peptides described in EP-A-0 629 347. The peptide according to the invention used was peptide 4, and the peptides according to EP-A-0 629 347 called Morinaga 10, Morinaga 11, Morinaga 12, and Morinaga 13.

The peptides were incubated with E. coli O14 and Candida albicans. Two concentrations of C. albicans yeast cells were tested,  $5 \cdot 10^6$  and  $5 \cdot 10^3$  per ml. Different concentrations of the peptides were tested.

After the incubation, samples were taken for bacterial plating. Serial dilutions of tenfold steps were used in the experiments marked with I in table 5 and of two-fold steps in the experiments marked with II.

The concentrations of the different agents required for killing of 100% of the bacteria are given in table 6.

Table 6

Agent	Concentration of agent for 100% killing ( $\mu\text{g/ml}$ )			
	E. coli O14		C. albicans	
	I	II	I	
			$5 \cdot 10^6$	$5 \cdot 10^3$
peptide 4	> 10, <100	12	> 10, <100	10
hLF	nd	nd	> 1000	> 2000
Morinaga 10	> 500	1000	> 2000	> 2000
Morinaga 11	> 500	nd	> 2000	> 2000
Morinaga 12	> 500	nd	> 2000	> 2000
Morinaga 13	> 500	nd	> 2000	> 2000

nd = not determined

From table 6 it is evident that the peptide according to the invention is a much more efficient bactericidal agent than the short peptides described in EP-A-0 629 347 and than human lactoferrin.

#### Example 8

The fungicidal and inhibitory activity of the peptide 2, peptide 3, peptide 4, and peptide 7 according to the invention were compared to the peptides described in EP-A-0 629 347 most resembling the peptides according to the invention, i.e. Morinaga 24 and Morinaga 25.

Candida albicans ATCC 64549 ( $1 \cdot 10^5/\text{ml}$ ) was incubated in the presence of the peptides during 2 hours at  $37^\circ\text{C}$  in diluted growth medium (BHI, twofold serial dilutions starting with  $50 \mu\text{g/ml}$ ). The fungicidal activity was measured by culturing  $5 \mu\text{l}$  from each incubation well on Saboroud agar plates. The concentrations of the different agents required for killing of 100% of the bacteria is given in table 7.

The inhibition of growth was measured spectrophotometrically after 20 hours of incubation. The concentration of agent needed for inhibition of growth is given in table 7.

5

Table 7

Agent	Concentration of agent for 100% killing ( $\mu\text{g/ml}$ )	Concentration of agent for inhibition of growth ( $\mu\text{g/ml}$ )
Peptide 2	6.2	6.2
Peptide 3	6.2	6.2
Peptide 4	6.2	6.2
Peptide 7	3.1	1.5
Morinaga 24	12.5	12.5
Morinaga 25	6.2	6.2

This example show that peptide 2, peptide 3, and peptide 4 according to the invention is more efficient with regard to fungicidal and inhibitory activity than the linear peptide Morinaga 24 and that peptide 7 according to the invention is an even better fungicidal agent and inhibitor of growth of fungi.

15

Example 9

Also the bactericidal and inhibitory activity of the peptide 2, peptide 3, peptide 4, and peptide 7 according to the invention were compared to the activities of Morinaga 24 and Morinaga 25.

20

*E. coli* O14 was incubated as described above in the presence of the peptides during 2 hours. The bactericidal activity was measured in the same way as described above. The concentrations of the different agents required for killing of 100% of the bacteria is given in table 8.

25

The inhibition of growth was measured spectrophotometrically after incubation during 20 hours. The con-

centration of agent needed for inhibition of growth is given in table 8.

Table 8

5

Agent	Concentration of agent for 100% killing ( $\mu\text{g/ml}$ )	Concentration of agent for inhibition of growth ( $\mu\text{g/ml}$ )
Peptide 2	25	6.2
Peptide 3	12.5	3.1
Peptide 4	12.5	3.1
Peptide 7	12.5	$\leq 1.5$
Morinaga 24	25	6.2
Morinaga 25	12.5	3.1

This example show that peptide 2, peptide 3 and peptide 4 according to the invention have bactericidal and inhibitory effects that are approximately the same as those for Morinaga 24 and Morinaga 25, but that peptide 7 is much more efficient with regards to inhibition of growth of bacteria.

Example 10

15 In this example, the microbicidal and microbiostatic activity of the peptides according to the invention were tested and compared to the two reference peptides.

C. albicans (ATCC64549) and E. coli O6, respectively, were incubated with the different peptides. The experiments were performed with 1, 10, 25 and 100  $\mu\text{g/ml}$  of peptide. The results are shown in table 9.

Table 9

Peptide	C. albicans		E. coli	
	MMC <sub>99%</sub>	MIC	MMC <sub>99%</sub>	MIC
Peptide 44	10	10	10	10
Peptide 46	10	10	10	10
Peptide 48	10	10	10	10
Peptide 50	10	10	10	10
Peptide 51	10	10	10	10
Peptide 53	10	10	10	10
Peptide 57	25	10	10	10
Peptide 61	10	10	10	10
Peptide 63	10	10	10	10
Peptide 64	25	10	10	10
Peptide 67	10	10	10	10
Peptide 40	25	25	> 25	> 25
Peptide 33	100	10	25	10

From the table, it is evident that the peptides according to the invention have very good microbicidal and microbiostatic activity, even though the shortest peptide, peptide 40, and the longest peptide, peptide 33, do not give as good results as the other peptides.

#### 10 Example 11

In this example the activities of the peptides according to the invention on the killing of *C. albicans* and on the inhibition of the growth of *C. albicans* were studied.

15 *C. albicans* yeast cells (ATCC64549) were incubated for 2 hours at pH 4.5 in BHI medium diluted to 1% of the original concentration containing 25 µg/ml of the peptide. Thereafter the fungal solutions were cultured on blood agar plates. OD<sub>650</sub> was measured after incubation  
20 during an additional 18 hours.

The fungicidal effect of the peptides on *C. albicans* was determined as the ability of the peptide to kill 100%



and 99%, respectively, of the fungus, while the growth inhibitory effect was determined by measuring the OD<sub>650</sub>. An inhibitory effect existed when no increase in OD<sub>650</sub> was recorded. The results are shown in table 10.

5

Table 10

Peptide	C. albicans		
	killing:		inhibition:
	100%	99%	
Peptide 44	-	-	-
Peptide 46	+	+	+
Peptide 48	+	+	+
Peptide 50	+	+	+
Peptide 51	+	+	+
Peptide 6	-	+	-
Peptide 57	+	+	+
Peptide 61	-	+	+
Peptide 62	-	+	+
Peptide 64	-	+	+
Peptide 66	-	+	+
Peptide 40	-	-	-
Peptide 33	-	-	-

killing: + = 100/99 % of the bacteria are killed  
 - = less than 100/99% of the bacteria are killed

10

inhibition: + = no increase in OD<sub>650</sub> is seen  
 - = OD<sub>650</sub> continues to increase

From the table, it is evident that the peptides according to the invention, especially Peptides 46, 48, 50, 51, and 57, have better effect on the killing and growth inhibition of C. albicans than the reference peptides.

15

Example 12

20

In this example, the peptides according to the invention were used to study the effect on the killing of

different bacteria. The different bacteria used are shown in table 11.

The peptides were used at a concentration of 25 µg/ml.

5 The results are shown in table 11.

Table 11

Peptide	Bacteria				
	E. faecalis	S. epidermis	S. aureus	K. pneumoniae	P. aeruginosa
Peptide 44	+	+	+	-	-
Peptide 46	+	+	+	+	+
Peptide 48	+	+	+	+	+
Peptide 50	+	+	+	+	+
Peptide 51	+	+	+	+	+
Peptide 6	+	+	+	+	+
Peptide 57	+	+	+	+	+
Peptide 61	+	+	+	+	+
Peptide 62	+	+	+	+	+
Peptide 64	+	+	+	-	-
Peptide 66	+	+	+	-	-
Peptide 40	-	+	-	-	-
Peptide 33	+	+	+	-	-

+ = 99% of the bacteria are killed

10 - = less than 99% of the bacteria are killed

From the table, it is evident that the peptides according to the invention, especially Peptides 46-62, have very good effect on the killing of bacteria, even though  
 15 the shortest peptide, peptide 40, and the longest peptide, peptide 33, do not give as good results as the other peptides.

#### Example 13

20 In this example the concentrations needed of three peptides according to the invention for killing of 99% of

C. albicans at different pH was compared to a reference peptide. The peptides according to the invention were peptide 2 (linear), peptide 3 (cyclic), peptide 4 (linear), peptide 5 (cyclic) and peptide 7 (lactam bridged), all capped. The reference peptides used were an uncapped cyclic form and an uncapped linear form of a Morinaga peptide, Morinaga 24 and 25. The results are illustrated in Fig. 2. From the figure it is evident that the capped, linear peptides 3, and 4 as well as the lactam bridge containing peptide 7 have better effects than the capped cyclic peptides according to the invention, and that all the capped linear peptides according to the invention in addition to peptide 7 have better effects than the linear and cyclic, uncapped reference peptides (Morinaga 24 and 25) at pH 4.5. The most effective peptide at all different pH was peptide 7.

#### Example 14

In this example prevention of C. albicans colonisation in stomach was studied by giving human lactoferrin (HFL), the peptide with SEQ. ID. NO. 3 and the peptide with SEQ. ID. NO. 4 perorally to mice. A dose of  $10^8$  of C. albicans was given intragstrically to mice. Three days later HLF or peptide was given twice a day (in a total of 1 mg per day) for three days, and on the fourth day the mice were killed. The number of C. albicans in the stomach was determined by culturing and counting colony-forming units (CFU per ml). The results are illustrated in figure 3. It is evident from the results that the peptides effectively reduce the growth of C. albicans in the stomach.

#### Example 15

In this example the anti-inflammatory effects of the peptides according to the invention on experimental colitis in mice were studied. Acute colitis was induced in C57B1/6J mice by giving dextranulphate (5%) via the

drinking water (ad lib). Peptide 3 and peptide 4, as well as human lactoferrin (hLF), were orally administered to mice at the start of dextran sulphate treatment. The animals were killed on day 2.

5        It was found that blood in faeces of mice treated with the peptides according to the invention occurred in fewer animals than compared to the water-treated control group two days after treatment, as shown in Fig. 4 A.

10       Another indication of the fact that the peptides according to the invention are anti-inflammatory, is the reduced concentrations of the inflammatory cytokine IL-1 $\beta$  present in sera from the mice treated according to the invention, as illustrated in Fig. 4 B, as well as the reduced occurrence of rectal bleeding, as shown in Fig. 4  
15       C.

Another measurement of inflammation in the colon is the colon length - a shortened colon is inductive of inflammation. It was found, as shown in Fig. 4 D, that the colon of the mice treated according to the invention were  
20       longer than the colon of the mice in the control group.

Thereafter the number of CD8- and MHC class II-positive cells in tissue sections of distal colon from the mice was studied, and the results are shown in Fig. 5. From Fig. 5 A, it is clear that the number of CD8-  
25       positive T-cells in tissue sections of distal colon from the mice treated with the peptides according to the invention is significantly lower than for the water-treated control group.

From Fig. 5 B it is clear that the occurrence of  
30       cells expressing MHC class II (macrophages, dendritic cells and B cells) in tissue sections of distal colon from the mice treated with the peptides according to the invention is higher than for the untreated control group, and similar to that of healthy animals with no acute colitis. These results indicate that mice treated with the  
35       peptides according to the invention diminish or delay their local cellular response.

Thus, the peptides according to the invention are effective in reducing the inflammation itself as well as the clinical symptoms.

5 Example 16

In this example the fungicidal activity of one of the peptides according to the invention, the peptide with SEQ. ID. NO. 7, was compared to the conventional antifungal agents flucytosine and fluconazole, and also to human lactoferrin (hLF). The antifungal agents were tested on  
10 C. albicans (ATCC 64549) in a concentration of  $2 \times 10^5$  cells/ml. The tests were performed in BHI medium diluted 1/100. The results are shown in table 12.

15 Table 12

Antifungal agent	MMC <sub>99%</sub> (µg/ml)	MIC (µg/ml)
Flucytosine <sup>*)</sup>	> 500	250
Fluconazole	> 500	> 500
hLF	> 1000	1000
Peptide 7	6.2	6.2

<sup>\*)</sup> This may be inhibited by nonsynthetic media, however a 1/100 dilution of the medium used herein diminishes this risk.

20 It is evident from the results in table 12 that the peptide according to the invention is clearly more effective than the other substances.

Example 17

25 Also in this example one of the peptides according to the invention - this time the peptide with SEQ. ID. NO. 4, was compared to a conventional fungicide, amphotericin. The antifungal activity against C. albicans was studied. Twofold serial dilutions with a starting concentration of 20 µg/ml were used. BHI diluted 1/100 was used  
30 as growth medium.

Table 13

Fungicidal agent	MMC <sub>99%</sub> (µg/ml)	MIC (µg/ml)
Peptide 4	5.0	5.0
Amphotericin	2.5	0.6

It is evident from table 13 that the activity of the  
5 peptide according to the invention is comparable to the  
conventional fungicide.

Example 18

In this example the bactericidal activity of two of  
10 the peptides according to the invention was studied in a  
test with a multiresistant *S. aureus*. A bacterial solu-  
tion with a concentration of  $5.0 \times 10^5$  *S. aureus* bacte-  
rial per ml was used. The concentration of each peptide  
needed to kill 99% of the bacteria (MMC<sub>99%</sub>) was determined  
15 after 2 hours and after 24 hours of incubation at 37°C .  
The results are illustrated in table 14 below.

Table 14

SEQ. ID. NO.	MMC <sub>99%</sub> (µg/ml)	
	2 hours	24 hours
4	5.0	≤ 0.32
48	5.0	≤ 0.32

20

Example 19

In this example the bactericidal activity of three  
of the peptides according to the invention was studied in  
a test with a reference strain of *S. aureus*. A bacterial  
25 solution with a concentration of  $5.0 \times 10^5$  *S. aureus* bac-  
terial per ml was used. The concentration of each peptide  
needed to kill 99% of the bacteria (MMC<sub>99%</sub>) was determined  
after 2 hours of incubation at 37°C. The lowest concen-  
tration tested was 6.25 µg/ml. The results are illus-  
30 trated in table 15 below.

Table 15

SEQ. ID. NO.	MMC <sub>99%</sub> (µg/ml) 2 hours
36	≤ 6.25
98	≤ 6.25
7	≤ 6.25

5 Example 20

In this example a so called alanine scan of the peptide with SEQ. ID. NO. 46, C-F-Q-W-Q-R-N-M-R-K-V-R, was performed. In this alanine scan each amino acid was in turn substituted with an alanine, resulting in the peptides illustrated in table 16 below.

Table 16

Exp. No.	amino acid in position												SEQ. ID. NO.
1	A	F	Q	W	Q	R	N	M	R	K	V	R	68
2	C	A	Q	W	Q	R	N	M	R	K	V	R	69
3	C	F	A	W	Q	R	N	M	R	K	V	R	70
4	C	F	Q	A	Q	R	N	M	R	K	V	R	71
5	C	F	Q	W	A	R	N	M	R	K	V	R	72
6	C	F	Q	W	Q	A	N	M	R	K	V	R	73
7	C	F	Q	W	Q	R	A	M	R	K	V	R	74
8	C	F	Q	W	Q	R	N	A	R	K	V	R	75
9	C	F	Q	W	Q	R	N	M	A	K	V	R	76
10	C	F	Q	W	Q	R	N	M	R	A	V	R	77
11	C	F	Q	W	Q	R	N	M	R	K	A	R	78
12	C	F	Q	W	Q	R	N	M	R	K	V	A	79

15 Example 21

In each of the experiments in this example one of the amino acids in positions 4, 6, 8 and 9 in the peptide with SEQ. ID. NO. 46 was replaced by a similar amino

acid. In experiment 1 the tryptophan in position 4 was replaced by a leucine, in experiment 2 the arginine in position 6 was replaced by a lysine, in experiment 3 the methionine in position 8 was replaced by a leucine, and in experiment 4 the arginine in position 9 was replaced by a lysine. The resulting peptides are illustrated in table 17.

Table 17

Exp. No.	amino acid in position												SEQ. ID. NO.
1	C	F	Q	L	Q	R	N	M	R	K	V	R	80
2	C	F	Q	W	Q	K	N	M	R	K	V	R	81
3	C	F	Q	W	Q	R	N	L	R	K	V	R	82
4	C	F	Q	W	Q	R	N	M	K	K	V	R	83

Example 22

In each of the experiments in this example one of the amino acids in positions 5, 6, and 7 in the peptide with SEQ. ID. NO. 46 was replaced by a negatively charged amino acid. In experiment 1 the glutamine in position 5 was replaced by a glutamic acid, in experiment 2 the arginine in position 6 was replaced by glutamic acid, and in experiment 3 the asparagine in position 7 was replaced by glutamic acid. The resulting peptides are illustrated in table 18.

Table 18

Exp. No.	amino acid in position												SEQ. ID. NO.
1	C	F	Q	W	E	R	N	M	R	K	V	R	84
2	C	F	Q	W	Q	E	N	M	R	K	V	R	85
3	C	F	Q	W	Q	R	E	M	R	K	V	R	86



Example 23

In each of the experiments in this example a neutral amino acid in the peptide with SEQ. ID. NO. 46 was replaced with either a positively charged amino acid or a neutral one. In experiment 1 the glutamine in position 5 was replaced by an ornithine, in experiment 2 the glutamine in position 5 was replaced by a norleucine, in experiment 3 the asparagine in position 7 was replaced by an ornithine, and in experiment 4 the asparagine in position 7 was replaced by a norleucine. The resulting peptides are illustrated in table 19.

Table 19

Exp. No.	amino acid in position												SEQ. ID. NO.
1	C	F	Q	W	Orn	R	N	M	R	K	V	R	87
2	C	F	Q	W	Nle	R	N	M	R	K	V	R	88
3	C	F	Q	W	Q	R	Orn	M	R	K	V	R	89
4	C	F	Q	W	Q	R	Nle	M	R	K	V	R	90

Example 24

In each of the experiments in this example one or several of the amino acids in the peptide with SEQ. ID. NO. 46 was replaced with other amino acids. In experiment 1 the glutamine in position 5 was replaced with a lysine, in experiment 2 the glutamine in position 5 was replaced with an lysine and the asparagine in position 7 was replaced by an alanine, in experiment 3 the glutamine in position 3 was replaced with an alanine and the glutamine in position 5 was replaced with an lysine, in experiment 4 the glutamine in position 3 and the asparagine in position 7 were replaced with alanines, in experiment 5 the tryptophan in position 4 was replaced with a leucine, and the arginines in position 6 and position 9 were replaced with lysines, and in experiment 6 the glutamine in position 3 and the asparagine in position 7 were replaced

with alanine, the tryptophan in position 4 was replaced with a leucine, and the glutamine in position 5 and the arginines in positions 6 and 9 were replaced with lysines. The resulting peptides are illustrated in table 20.

5

Table 20

Exp. No.	amino acid in position												SEQ. ID. NO.
	1	2	3	4	5	6	7	8	9	10	11	12	
1	C	F	Q	W	K	R	N	M	R	K	V	R	91
2	C	F	Q	W	K	R	A	M	R	K	V	R	92
3	C	F	A	W	K	R	N	M	R	K	V	R	93
4	C	F	A	W	Q	R	A	M	R	K	V	R	94
5	C	F	Q	L	Q	K	N	M	K	K	V	R	95
6	C	F	A	L	K	K	A	M	K	K	V	R	96

Example 25

10 In this example the fungicidal, and bactericidal effects of the different peptides obtained in examples 18-21 were studied. *C. albicans*, *E. coli* and *S. aureus*, respectively, were incubated in BHI medium diluted 1/100, with a pH of approximately 6.7-6.9. The concentration of  
15 each peptide needed to kill 99% of the microorganisms (MMC<sub>99%</sub>) was determined. The results are illustrated in table 21 below.

Table 21

SEQ. ID. NO.	MMC <sub>99%</sub>		
	C. albicans	E. coli	S. aureus
46	12	12	7
68	12	>25	28
69	12	12	14
70	6	6	7
71	12	25	14
72	12	12	7
73	12	12	7
74	6	6	3.5
75	25	12	7
76	25	25	7
77	25	12	7
78	25	12	7
79	25	12	7
80	6	12	7
81	6	6	7
82	6	12	7
83	6	6	7
84	12	25	14
85	>50	>25	>28
86	25	25	14
87	3	6	≤3.5
88	6	12	3.5
89	6	6	3.5
90	12	12	3.5

Example 26

5           In this example the fungicidal, and bacteri-  
 cidal effects of the different peptides obtained in exam-  
 ple 22 were studied. C. albicans, E. coli and S. aureus,  
 respectively, were incubated in BHI medium diluted 1/100,  
 with a pH of approximately 6.7-6.9. The concentration of  
 10 each peptide needed to kill 99% of the microorganisms

(MMC<sub>99%</sub>) was determined. The results are illustrated in table 22 below.

Table 22

5

SEQ. ID. NO.	MMC <sub>99%</sub>		
	C. albicans	E. coli	S. aureus
46	12	6	12
91 <sup>*)</sup>	6	6	6
93	12	6	6
94	12	6	6
95	12	6	6
96	12	6	12
97	12	6	6

<sup>\*)</sup> The peptide with SEQ. ID. NO. 91 was tested twice, and the results were the same at both times.

Example 27

10 In this example the fungicidal activity of three of the peptides according to the invention was studied, and tested against three different fungi. The fungi were incubated in BHI medium diluted 1/100. The concentration of each peptide needed to kill 99% of the fungi (MMC<sub>99%</sub>) was  
15 determined. The results are illustrated in table 23 below.

Table 23

SEQ. ID. NO.	MMC <sub>99%</sub>		
	C. albicans	C. glabrata	C. neoformans
4	6.3	>50	≤3.1
46	12.5	50	ND
87	6.3	>50	3.1

Example 28

In this example the microbicidal activity of eight of the peptides according to the invention was studied, and tested against E. coli O6K5 and C. albicans.

5 In this example, a peptide with SEQ. ID. NO. 55 was used, which has not been described above. This peptide is a modification of the peptide with SEQ. ID. NO. 7 wherein the Asp in position 9 is substituted with a Glu.

10 The concentration of each peptide needed to kill 99% of the microorganisms (MMC<sub>99%</sub>) was determined. The results are illustrated in table 24 below.

Table 24

SEQ. ID. NO.	MMC <sub>99%</sub>	
	E. coli	C. albicans
4	20	5
7	> 20	5
55	5	5
46	10	10
87	5	5
88	5	10
91	5	5
93	5	5

15

The conclusion of the results of tables 21-24 is that the peptide sequence can be modified at several positions and by that increase or keep the microbicidal activity compared with the natural sequence. These modified sequences also reduce the costs for synthesis of the peptides. The positions at which amino acids can be changed with better or equal results are the ones denoted Xaa in SEQ. ID. NO. 99.

20

CLAIMS

1. A peptide the sequence of which is based on the sequence constituted of the amino acids 12-40 of human lactoferrin counted from the N-terminal end, a modified  
5 version thereof, or a fragment thereof.

2. A peptide according to claim 1, the sequence of which is SEQ. ID. NO. 1 given in the appended sequence listing wherein X in position 1 is E or none, X in position 2 is A or none, X in position 5 is C or A, X in position 7 is Q or K, X in position 11 is N or D, and X in  
10 positions 17-25 are -G-P-P-V-S-C-I-K-R or none, or functionally equivalent homologues or analogues thereof.

3. A peptide according to claim 2, wherein X in position 1 is E, X in position 2 is A, X in position 5 is C, X in position 7 is Q, X in position 11 is N, and X in  
15 positions 17-25 are -G-P-P-V-S-C-I-K-R, the sequence thus being SEQ. ID. NO. 2 given in appended sequence listing, or functionally equivalent homologues or analogues thereof.

20 4. A peptide according to claim 3 which is cyclised through a disulphide bridge, the sequence thus being SEQ. ID. NO. 3 given in the appended sequence listing, or functionally equivalent homologues or analogues thereof.

5. A peptide according to claim 2, wherein X in position 1 is none, X in position 2 is none, X in position 5 is C, X in position 7 is Q, X in position 11 is N, and X in positions 17-25 are is -G-P-P-V-S-C-I-K-R, the sequence thus being SEQ. ID. NO. 4 given in the appended  
25 sequence listing, or functionally equivalent homologues or analogues thereof.  
30

6. A peptide according to claim 5 which is cyclised through a disulphide bridge, the sequence thus being SEQ. ID. NO. 5 given in the appended sequence listing, or functionally equivalent homologues or analogues thereof.

35 7. A peptide according to claim 2, wherein X in position 1 is none, X in position 2 is none, X in position 5 is A, X in position 7 is K, X in position 11 is D, and X

in positions 17-25 are none, the sequence thus being SEQ. ID. NO. 6 given in the appended sequence listing, or functionally equivalent homologues or analogues thereof.

5 8. A peptide according to claim 7, wherein a lactam bridge is formed between the amino acids K in position 5 and D in position 9, the sequence thus being SEQ. ID. NO. 7 given in the appended sequence listing, or functionally equivalent homologues or analogues thereof.

10 9. A peptide according to claim 1, the sequence of which is SEQ. ID. NO. 8 given in appended the sequence listing or a fragment of said sequence consisting of at least 7 amino acids, or functionally equivalent homologues or analogues thereof.

15 10. A peptide according to claim 9, consisting of only 7 amino acids, the sequence thus being any of SEQ. ID. NO. 9-22 given in the appended sequence listing, or functionally equivalent homologues or analogues thereof.

20 11. A peptide according to claim 9, the sequence being any of SEQ. ID. NO. 13 and SEQ. ID. NO. 23-31 given in the appended sequence listing, or functionally equivalent homologues or analogues thereof.

25 12. A peptide according to claim 9, the sequence being any of SEQ. ID. NO. 22 and 31-42 given in the appended sequence listing, or functionally equivalent homologues or analogues thereof.

13. A peptide according to claim 1, consisting of 11 - 17 amino acids comprising the sequence SEQ. ID. NO. 43, or functionally equivalent homologues or analogues thereof.

30 14. A peptide according to claim 13, wherein the amino acids denoted by Xaa are, independently of each other, Q, K, D, N, or V.

35 15. A peptide according to claim 14, having one of the sequences SEQ. ID. NO. 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64 or 66, or functionally equivalent homologues or analogues thereof.

16. A peptide according to claim 15, having one of the sequences SEQ. ID. NO. 50, 52, 54, 56, 60 or 98, or functionally equivalent homologues or analogues thereof.

17. A peptide according to claim 14, wherein the N-terminal amino acid is acetylated and/or the C-terminal amino acid is amidated.

18. A peptide according to claim 17, having one of the sequences SEQ. ID. NO. 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65 or 67, or functionally equivalent homologues or analogues thereof.

19. A peptide according to claim 18, having one of the sequences SEQ. ID. NO. 51, 53, 55, 57, 59 61 or 97, or functionally equivalent homologues or analogues thereof.

20. A peptide according to claim 13 or 14, having a sequence essentially corresponding to one of SEQ. ID. NO. 46-51 and 62-67 but wherein the cysteine has been replaced by an acetamidomethyl-cysteine, or functionally equivalent homologues or analogues thereof.

21. A peptide according to claim 1, consisting of 12 amino acids, the sequence of which is SEQ. ID. NO. 99, wherein Xaa in position 3 is preferably Gln or Ala, Xaa in position 4 is preferably Trp or Leu, Xaa in position 5 is preferably Gln, Lys, Orn, Ala or Nle, Xaa in position 6 is preferably Arg, Lys or Ala, Xaa in position 7 is preferably Asn, Orn, Ala or Nle, Xaa in position 8 is preferably Met or Leu, and Xaa in position 9 is preferably Arg or Lys.

22. A peptide according to claim 21, the sequence of which is any of SEQ. ID. NO. 68-96 given in the appended sequence listing.

23. A peptide according to claim 22, having SEQ. ID. NO. 70 or SEQ. ID. NO. 74.

24. A peptide according to claim 22, having SEQ. ID. NO. 81 or SEQ. ID. NO. 83.

25. A peptide according to claim 22, having SEQ. ID. NO. 87 or SEQ. ID. NO. 89.



26. A peptide according to claim 22, having SEQ. ID. NO. 91.

27. A medicinal product comprising a peptide according to any of the claims 1-26.

5 28. A medicinal product according to claim 27 for treatment and/or prevention of infections, inflammations and/or tumours.

29. A medicinal product according to claim 28, for treatment and/or prevention of urinary tract infection.

10 30. A medicinal product according to claim 28, for treatment and/or prevention of colitis.

31. A medicinal product according to claim 28, for treatment of a candida infection on a mucosal membrane.

15 32. A medicinal product according to any one of the claims 27-31 formulated for oral administration.

33. A medicinal product according to any one of the claims 27-31 formulated for parenteral administration.

34. A medicinal product according to claim 33 formulated for topical administration.

20 35. A medicinal product according to any one of the claims 27-34 formulated for administration on mucosal membranes.

36. Food stuff comprising a peptide according to any of the claims 1-26.

25 37. Food stuff according to claim 36 being an infant formula food.

38. Use of a peptide according to any one of the claims 1-26 for the production of a medicinal product for treatment and/or prevention of infections, inflammations and/or tumours.

30 39. Use according to claim 38, wherein the medicinal product is intended for treatment and/or prevention of urinary tract infection.

40. Use according to claim 38, wherein the medicinal product is intended for treatment and/or prevention of colitis.

41. Use according to claim 38, wherein the medicinal product is intended for treatment of a candida infection on a mucosal membrane.

42. Use according to any one of the claims 38-41, wherein the medicinal product is formulated for oral administration.

43. Use according to any one of the claims 38-41, wherein the medicinal product is formulated for parenteral administration.

44. Use according to claim 43, wherein the medicinal product is formulated for topical administration.

45. Use according to any one of the claims 38-44, wherein the medicinal product is formulated for administration on mucosal membranes.

46. Use according to claim 42, wherein the medicinal product constitutes or is included in a food stuff.

47. Use according to claim 46, wherein the food stuff is an infant formula food.

48. A method for treatment or prevention of infections, inflammations or tumours wherein an effective amount of a substance chosen from the group consisting of the peptides having any of the sequences SEQ ID NO 1-99, fragments, and functionally equivalent homologues and analogues thereof, is administered to a patient.

49. A method according to claim 48 for treatment and/or prevention of urinary tract infection.

50. A method according to claim 48 for treatment and/or prevention of colitis.

51. A method according to claim 48 for treatment and/or prevention of a candida infection on a mucosal membrane.

52. A method according to claim 48, wherein the substance is orally administered.


53. A method according to claim 48, wherein the substance is parenterally administered.


54. A method according to claim 53, wherein the substance is topically administered.


55. A method according to claim 54, wherein the substance is administered on mucosal membranes.

56. A method according to claim 52, wherein the substance is included in a food stuff.

5 57. A method according to claim 56, wherein the substance is included in an infant formula food.

*Figure 1*

*Fig. 2*

***C. albicans* in stomach*****Fig. 3***

## Colitis in C57Bl/6 mice






Fig. 4

5/5

## Colitis CD8, day 2

**Fig. 5**



## SEQUENCE LISTING

<110> A+ Science Invest AB  
Mattsby-Baltzer, Inger  
Hanson Å, Lars  
Dolphin T, Gunnar

<120> NEW PEPTIDES AND USE THEREOF

<130> p2996317

<140>  
<141>

<150> 9802441-7  
<151> 1998-07-06

<150> 9802562-0  
<151> 1998-07-17

<150> 9804614-7  
<151> 1998-12-29

<160> 100

<170> PatentIn Ver. 2.1

<210> 1  
<211> 25  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to a modification of  
the sequence consisting of aa 16-40 in human  
lactoferrin

<220>  
<221> MOD\_RES  
<222> (1)  
<223> ACETYLATION

<220>  
<221> MOD\_RES  
<222> (25)  
<223> AMIDATION

&lt;400&gt; 1

Xaa Xaa Thr Lys Xaa Phe Xaa Trp Gln Arg Xaa Met Arg Lys Val Arg  
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
20 25

&lt;210&gt; 2

&lt;211&gt; 25

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to a modification of  
the sequence consisting of aa 16-40 in human  
lactoferrin

&lt;220&gt;

&lt;221&gt; MOD\_RES

&lt;222&gt; (1)

&lt;223&gt; ACETYLTATION

&lt;220&gt;

&lt;221&gt; MOD\_RES

&lt;222&gt; (25)

&lt;223&gt; AMIDATION

&lt;400&gt; 2

Glu Ala Thr Lys Cys Phe Gln Trp Gln Arg Asn Met Arg Lys Val Arg  
1 5 10 15

Gly Pro Pro Val Ser Cys Ile Lys Arg  
20 25

&lt;210&gt; 3

&lt;211&gt; 25

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to a modification of  
the sequence consisting of aa 16-40 in human

lactoferrin

&lt;220&gt;

&lt;221&gt; MOD\_RES

&lt;222&gt; (1)

&lt;223&gt; ACETYLATION

&lt;220&gt;

&lt;221&gt; MOD\_RES

&lt;222&gt; (25)

&lt;223&gt; AMIDATION

&lt;220&gt;

&lt;221&gt; DISULFID

&lt;222&gt; (5)..(22)

&lt;400&gt; 3

Glu Ala Thr Lys Cys Phe Gln Trp Gln Arg Asn Met Arg Lys Val Arg

1

5

10

15

Gly Pro Pro Val Ser Cys Ile Lys Arg

20

25

&lt;210&gt; 4

&lt;211&gt; 23

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to a modification of  
the sequence consisting of aa 18-40 in human  
lactoferrin

&lt;220&gt;

&lt;221&gt; MOD\_RES

&lt;222&gt; (1)

&lt;223&gt; ACETYLATION

&lt;220&gt;

&lt;221&gt; MOD\_RES

&lt;222&gt; (23)

&lt;223&gt; AMIDATION

&lt;400&gt; 4

Thr Lys Cys Phe Gln Trp Gln Arg Asn Met Arg Lys Val Arg Gly Pro

<220>  
<223> Description of Artificial Sequence: of natural or

artificial origin, corresp. to a modification of  
the sequence consisting of aa 18-31 in human  
lactoferrin

<220>

<221> MOD\_RES

<222> (1)

<223> ACETYLATION

<220>

<221> MOD\_RES

<222> (14)

<223> AMIDATION

<400> 6

Thr Lys Ala Phe Lys Trp Gln Arg Asp Met Arg Lys Val Arg  
1 5 10

<210> 7

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to a modification of  
the sequence consisting of aa 18-31 in human  
lactoferrin; a lactam is formed between aa 5 and 9

<220>

<221> MOD\_RES

<222> (1)

<223> ACETYLATION

<220>

<221> MOD\_RES

<222> (14)

<223> AMIDATION

<220>

<221> BINDING

<222> (5) .. (9)

<223> LACTAM

<400> 7

Thr Lys Ala Phe Lys Trp Gln Arg Asp Met Arg Lys Val Arg

- 1                      5                      10

```
<210> 8
<211> 20
<212> PRT
<213> Artificial Sequence
```

<220>  
<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 12-31 in human lactoferrin

```
<400> 8
Val Ser Gln Pro Glu Ala Thr Lys Cys Phe Gln Trp Gln Arg Asn Met
      1           5           10           15
```

Arg Lys Val Arg  
20

```
<210> 9
<211> 7
<212> PRT
<213> Artificial Sequence
```

<220>  
<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 12-18 in human lactoferrin

```
<400> 9
Val Ser Gln Pro Glu Ala Thr
      1             5
```

```
<210> 10
<211> 7
<212> PRT
<213> Artificial Sequence
```

<220>  
<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 13-19 in human lactoferrin

<400> 10

Ser Gln Pro Glu Ala Thr Lys

1

5

<210> 11

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 14-20 (SEQ. ID. 11) or 19-31  
(SEQ. ID. 37) in human lactoferrin

<400> 11

Gln Pro Glu Ala Thr Lys Cys

1

5

<210> 12

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to a modification of  
the sequence consisting of aa 15-21 in human  
lactoferrin

<400> 12

Pro Glu Ala Thr Lys Cys Phe

1

5

<210> 13

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or

artificial origin, corresp. to the sequence  
consisting of aa 16-22 in human lactoferrin

<400> 13

Glu Ala Thr Lys Cys Phe Gln

1

5

<210> 14

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 17-23 in human lactoferrin

<400> 14

Ala Thr Lys Cys Phe Gln Trp

1

5

<210> 15

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 18-24 in human lactoferrin

<400> 15

Thr Lys Cys Phe Gln Trp Gln

1

5

<210> 16

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or



artificial origin, corresp. to the sequence  
consisting of aa 19-25 in human lactoferrin

<400> 16

Lys Cys Phe Gln Trp Gln Arg

1

5

<210> 17

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 20-26 in human lactoferrin

<400> 17

Cys Phe Gln Trp Gln Arg Asn

1

5

<210> 18

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 21-27 in human lactoferrin

<400> 18

Phe Gln Trp Gln Arg Asn Met

1

5

<210> 19

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or

artificial origin, corresp. to the sequence  
consisting of aa 22-28 in human lactoferrin

<400> 19

Gln Trp Gln Arg Asn Met Arg

1

5

<210> 20

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 23-29 in human lactoferrin

<400> 20

Trp Gln Arg Asn Met Arg Lys

1

5

<210> 21

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 24-30 in human lactoferrin

<400> 21

Gln Arg Asn Met Arg Lys Val

1

5

<210> 22

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or

artificial origin, corresp. to the sequence  
consisting of aa 25-31 in human lactoferrin

<400> 22

Arg Asn Met Arg Lys Val Arg

1

5

<210> 23

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 16-23 in human lactoferrin

<400> 23

Glu Ala Thr Lys Cys Phe Gln Trp

1

5

<210> 24

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 16-24 in human lactoferrin

<400> 24

Glu Ala Thr Lys Cys Phe Gln Trp Gln

1

5

<210> 25

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or

artificial origin, corresp. to the sequence  
consisting of aa 16-25 in human lactoferrin

<400> 25

Glu Ala Thr Lys Cys Phe Gln Trp Gln Arg  
1 5 10

<210> 26

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 16-26 in human lactoferrin

<400> 26

Glu Ala Thr Lys Cys Phe Gln Trp Gln Arg Asn  
1 5 10

<210> 27

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 16-27 in human lactoferrin

<400> 27

Glu Ala Thr Lys Cys Phe Gln Trp Gln Arg Asn Met  
1 5 10

<210> 28

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or

artificial origin, corresp. to the sequence  
consisting of aa 16-28 in human lactoferrin

<400> 28

Glu Ala Thr Lys Cys Phe Gln Trp Gln Arg Asn Met Arg  
1 5 10

<210> 29

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 16-29 in human lactoferrin

<400> 29

Glu Ala Thr Lys Cys Phe Gln Trp Gln Arg Asn Met Arg Lys  
1 5 10

<210> 30

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 16-30 in human lactoferrin

<400> 30

Glu Ala Thr Lys Cys Phe Gln Trp Gln Arg Asn Met Arg Lys Val  
1 5 10 15

<210> 31

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or

artificial origin, corresp. to the sequence  
consisting of aa 16-31 in human lactoferrin

<400> 31

Glu	Ala	Thr	Lys	Cys	Phe	Gln	Trp	Gln	Arg	Asn	Met	Arg	Lys	Val	Arg
1				5					10					15	

<210> 32

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 13-31 in human lactoferrin

<400> 32

Ser	Gln	Pro	Glu	Ala	Thr	Lys	Cys	Phe	Gln	Trp	Gln	Arg	Asn	Met	Arg
1				5					10					15	

Lys Val Arg

<210> 33

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 14-31 in human lactoferrin

<400> 33

Gln	Pro	Glu	Ala	Thr	Lys	Cys	Phe	Gln	Trp	Gln	Arg	Asn	Met	Arg	Lys
1				5					10					15	

Val Arg

<210> 34

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 15-31 in human lactoferrin

<400> 34

Pro	Glu	Ala	Thr	Lys	Cys	Phe	Gln	Trp	Gln	Arg	Asn	Met	Arg	Lys	Val
1				5					10					15	

Arg

<210> 35

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 17-31 in human lactoferrin

<400> 35

Ala	Thr	Lys	Cys	Phe	Gln	Trp	Gln	Arg	Asn	Met	Arg	Lys	Val	Arg
1				5					10				15	

<210> 36

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 18-31 in human lactoferrin

<400> 36

Thr	Lys	Cys	Phe	Gln	Trp	Gln	Arg	Asn	Met	Arg	Lys	Val	Arg
1				5					10				

<210> 37

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or artificial origin, corresp. to the sequence consisting of aa 14-20 (SEQ. ID. 11) or 19-31 (SEQ. ID. 37) in human lactoferrin

<400> 37

Lys Cys Phe Gln Trp Gln Arg Asn Met Arg Lys Val Arg  
1 5 10

<210> 38

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or artificial origin, corresp. to the sequence consisting of aa 20-31 in human lactoferrin

<400> 38

Cys Phe Gln Trp Gln Arg Asn Met Arg Lys Val Arg  
1 5 10

<210> 39

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or artificial origin, corresp. to the sequence consisting of aa 21-31 in human lactoferrin

<400> 39

Phe Gln Trp Gln Arg Asn Met Arg Lys Val Arg  
1 5 10



<210> 40

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 22-31 in human lactoferrin

<400> 40

Gln Trp Gln Arg Asn Met Arg Lys Val Arg

1 5 10

<210> 41

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 23-31 in human lactoferrin

<400> 41

Trp Gln Arg Asn Met Arg Lys Val Arg

1 5

<210> 42

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 24-31 in human lactoferrin

<400> 42

Gln Arg Asn Met Arg Lys Val Arg

1 5

<210> 43

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or artificial origin, corresp. to a modification of the sequence consisting of aa 21-31 in human lactoferrin

<400> 43

Phe Xaa Trp Xaa Arg Xaa Met Arg Lys Xaa Arg  
1 5 10

<210> 44

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or artificial origin, corresp. to the sequence consisting of aa 21-31 in human lactoferrin

<400> 44

Phe Gln Trp Gln Arg Asn Met Arg Lys Val Arg  
1 5 10

<210> 45

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or artificial origin, corresp. to the sequence consisting of aa 21-31 in human lactoferrin

<400> 45

Phe Gln Trp Gln Arg Asn Met Arg Lys Val Arg

1 5 10

<210> 46

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 20-31 in human lactoferrin

<400> 46

Cys Phe Gln Trp Gln Arg Asn Met Arg Lys Val Arg  
1 5 10

<210> 47

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 20-31 in human lactoferrin

<220>

<221> MOD\_RES

<222> (1)

<223> ACETYLATION

<220>

<221> MOD\_RES

<222> (12)

<223> AMIDATION

<400> 47

Cys Phe Gln Trp Gln Arg Asn Met Arg Lys Val Arg  
1 5 10

<210> 48

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 19-31 in human lactoferrin

<400> 48

Lys Cys Phe Gln Trp Gln Arg Asn Met Arg Lys Val Arg  
1 5 10

<210> 49

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 19-31 in human lactoferrin

<220>

<221> MOD\_RES

<222> (1)

<223> ACETYLATION

<220>

<221> MOD\_RES

<222> (13)

<223> AMIDATION

<400> 49

Lys Cys Phe Gln Trp Gln Arg Asn Met Arg Lys Val Arg  
1 5 10

<210> 50

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to a the sequence

consisting of aa 18-31 in human lactoferrin

<400> 50

Thr Lys Cys Phe Gln Trp Gln Arg Asn Met Arg Lys Val Arg  
1 5 10

<210> 51

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 18-31 in human lactoferrin

<220>

<221> MOD\_RES

<222> (1)

<223> ACETYLTATION

<220>

<221> MOD\_RES

<222> (14)

<223> AMIDATION

<400> 51

Thr Lys Cys Phe Gln Trp Gln Arg Asn Met Arg Lys Val Arg  
1 5 10

<210> 52

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to a modification of  
the sequence consisting of aa 18-31 in human  
lactoferrin

<400> 52

Thr Lys Ala Phe Lys Trp Gln Arg Asp Met Arg Lys Val Arg  
1 5 10

<210> 53  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to a modification of  
the sequence consisting of aa 18-31 in human  
lactoferrin

<220>  
<221> MOD\_RES  
<222> (1)  
<223> ACETYLATION

<220>  
<221> MOD\_RES  
<222> (14)  
<223> AMIDATION

<400> 53  
Thr Lys Ala Phe Lys Trp Gln Arg Glu Met Arg Lys Val Arg  
1 5 10

<210> 54  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to a modification of  
the sequence consisting of aa 18-31 in human  
lactoferrin; a lactam is formed between aa 5 and 9

<220>  
<221> BINDING  
<222> (5) .. (9)  
<223> LACTAM

<400> 54  
Thr Lys Ala Phe Lys Trp Gln Arg Asp Met Arg Lys Val Arg

1 5 10

<210> 55

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to a modification of  
the sequence consisting of aa 18-31 in human  
lactoferrin; a lactam is formed between aa 5 and 9

<220>

<221> MOD\_RES

<222> (1)

<223> ACETYLTATION

<220>

<221> MOD\_RES

<222> (14)

<223> AMIDATION

<220>

<221> BINDING

<222> (5) .. (9)

<223> LACTAM

<400> 55

Thr Lys Ala Phe Lys Trp Gln Arg Glu Met Arg Lys Val Arg

1

5

10

<210> 56

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to a modification of  
the sequence consisting of aa 18-31 in human  
lactoferrin

<400> 56

Thr Lys Lys Phe Gln Trp Gln Arg Asn Met Arg Lys Val Arg  
1 5 10

<210> 57

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to a modification of  
the sequence consisting of aa 18-31 in human  
lactoferrin

<220>

<221> MOD\_RES

<222> (1)

<223> ACETYLATION

<220>

<221> MOD\_RES

<222> (14)

<223> AMIDATION

<400> 57

Thr Lys Lys Phe Gln Trp Gln Arg Asn Met Arg Lys Val Arg  
1 5 10

<210> 58

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to a modification of  
the sequence consisting of aa 18-31 in human  
lactoferrin

<400> 58

Thr Lys Lys Phe Gln Trp Asp Arg Lys Met Arg Lys Asp Arg  
1 5 10



<210> 59

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or artificial origin, corresp. to a modification of the sequence consisting of aa 18-31 in human lactoferrin

<220>

<221> MOD\_RES

<222> (1)

<223> ACETYLATION

<220>

<221> MOD\_RES

<222> (14)

<223> AMIDATION

<400> 59

Thr	Lys	Lys	Phe	Gln	Trp	Asp	Arg	Lys	Met	Arg	Lys	Asp	Arg
1					5						10		

<210> 60

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or artificial origin, corresp. to a modification of the seq. consisting of aa 18-31 in human lactoferrin; lactams formed between aa 3 and 7, and 9 and 13

<220>

<221> BINDING

<222> (3)..(7)

<223> LACTAM

<220>

<221> BINDING

<222> (9)..(13)

<223> LACTAM

<400> 60

Thr Lys Lys Phe Gln Trp Asp Arg Lys Met Arg Lys Asp Arg  
1 5 10

<210> 61

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to a modification of  
the seq. consisting of aa 18-31 in human  
lactoferrin; lactams formed between aa 3 and 7,  
and 9 and 13

<220>

<221> MOD\_RES

<222> (1)

<223> ACETYLTATION

<220>

<221> MOD\_RES

<222> (14)

<223> AMIDATION

<220>

<221> BINDING

<222> (3) .. (7)

<223> LACTAM

<220>

<221> BINDING

<222> (9) .. (13)

<400> 61

Thr Lys Lys Phe Gln Trp Asp Arg Lys Met Arg Lys Asp Arg  
1 5 10

<210> 62

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 17-31 in human lactoferrin

<400> 62

Ala	Thr	Lys	Cys	Phe	Gln	Trp	Gln	Arg	Asn	Met	Arg	Lys	Val	Arg
1				5				10					15	

<210> 63

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to a modification of  
the sequence consisting of aa 17-31 in human  
lactoferrin

<220>

<221> MOD\_RES

<222> (1)

<223> ACETYLATION

<220>

<221> MOD\_RES

<222> (15)

<223> AMIDATION

<400> 63

Ala	Thr	Lys	Cys	Phe	Gln	Trp	Gln	Arg	Asn	Met	Arg	Lys	Val	Arg
1				5				10					15	

<210> 64

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence

consisting of aa 16-31 in human lactoferrin

<400> 64

Glu Ala Thr Lys Cys Phe Gln Trp Gln Arg Asn Met Arg Lys Val Arg  
1 5 10 15

<210> 65

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to a modification of  
the sequence consisting of aa 16-31 in human  
lactoferrin

<220>

<221> MOD\_RES

<222> (1)

<223> ACETYLTATION

<220>

<221> MOD\_RES

<222> (16)

<223> AMIDATION

<400> 65

Glu Ala Thr Lys Cys Phe Gln Trp Gln Arg Asn Met Arg Lys Val Arg  
1 5 10 15

<210> 66

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 15-31 in human lactoferrin

<400> 66

Pro Glu Ala Thr Lys Cys Phe Gln Trp Gln Arg Asn Met Arg Lys Val  
1 5 10 15

Arg

<210> 67

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or artificial origin, corresp. to a modification of the sequence consisting of aa 15-31 in human lactoferrin

<220>

<221> MOD\_RES

<222> (1)

<223> ACETYLATION

<220>

<221> MOD\_RES

<222> (17)

<223> AMIDATION

<400> 67

Pro Glu Ala Thr Lys Cys Phe Gln Trp Gln Arg Asn Met Arg Lys Val

1

5

10

15

Arg

<210> 68

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or artificial origin, corresp. to the sequence consisting of aa 20-31 in human lactoferrin wherein one aa has been substituted

<400> 68

Ala Phe Gln Trp Gln Arg Asn Met Arg Lys Val Arg  
1 5 10

<210> 69

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 20-31 in human lactoferrin  
wherein one aa has been substituted

<400> 69

Cys Ala Gln Trp Gln Arg Asn Met Arg Lys Val Arg  
1 5 10

<210> 70

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 20-31 in human lactoferrin  
wherein one aa has been substituted

<400> 70

Cys Phe Ala Trp Gln Arg Asn Met Arg Lys Val Arg  
1 5 10

<210> 71

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 20-31 in human lactoferrin

wherein one aa has been substituted

<400> 71

Cys Phe Gln Ala Gln Arg Asn Met Arg Lys Val Arg  
1 5 10

<210> 72

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 20-31 in human lactoferrin  
wherein one aa has been substituted

<400> 72

Cys Phe Gln Trp Ala Arg Asn Met Arg Lys Val Arg  
1 5 10

<210> 73

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 20-31 in human lactoferrin  
wherein one aa has been substituted

<400> 73

Cys Phe Gln Trp Gln Ala Asn Met Arg Lys Val Arg  
1 5 10

<210> 74

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or artificial origin, corresp. to the sequence consisting of aa 20-31 in human lactoferrin wherein one aa has been substituted

<400> 74

Cys Phe Gln Trp Gln Arg Ala Met Arg Lys Val Arg  
1 5 10

<210> 75

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or artificial origin, corresp. to the sequence consisting of aa 20-31 in human lactoferrin wherein one aa had been substituted

<400> 75

Cys Phe Gln Trp Gln Arg Asn Ala Arg Lys Val Arg  
1 5 10

<210> 76

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or artificial origin, corresp. to the sequence consisting of aa 20-31 in human lactoferrin wherein one aa has been substituted

<400> 76

Cys Phe Gln Trp Gln Arg Asn Met Ala Lys Val Arg  
1 5 10

<210> 77

<211> 12

<212> PRT



<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or artificial origin, corresp. to the sequence consisting of aa 20-31 in human lactoferrin wherein one aa has been substituted

<400> 77

Cys Phe Gln Trp Gln Arg Asn Met Arg Ala Val Arg  
1 5 10

<210> 78

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or artificial origin, corresp. to the sequence consisting of aa 20-31 in human lactoferrin wherein one aa has been substituted

<400> 78

Cys Phe Gln Trp Gln Arg Asn Met Arg Lys Ala Arg  
1 5 10

<210> 79

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or artificial origin, corresp. to the sequence consisting of aa 20-31 in human lactoferrin wherein one aa has been substituted

<400> 79

Cys Phe Gln Trp Gln Arg Asn Met Arg Lys Val Ala  
1 5 10

<210> 80  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 20-31 in human lactoferrin  
wherein one aa has been substituted

<400> 80  
Cys Phe Gln Leu Gln Arg Asn Met Arg Lys Val Arg  
1 5 10

<210> 81  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 20-31 in human lactoferrin  
wherein one aa has been substituted

<400> 81  
Cys Phe Gln Trp Gln Lys Asn Met Arg Lys Val Arg  
1 5 10

<210> 82  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 20-31 in human lactoferrin  
wherein one aa has been substituted

<400> 82  
Cys Phe Gln Trp Gln Arg Asn Leu Arg Lys Val Arg  
1 5 10

<210> 83  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 20-31 in human lactoferrin  
wherein one aa has been substituted

<400> 83  
Cys Phe Gln Trp Gln Arg Asn Met Lys Lys Val Arg  
1 5 10

<210> 84  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 20-31 in human lactoferrin  
wherein one aa has been substituted

<400> 84  
Cys Phe Gln Trp Glu Arg Asn Met Arg Lys Val Arg  
1 5 10

<210> 85  
<211> 12  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 20-31 in human lactoferrin  
wherein one aa has been substituted

&lt;400&gt; 85

Cys Phe Gln Trp Gln Glu Asn Met Arg Lys Val Arg  
1 5 10

&lt;210&gt; 86

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 20-31 in human lactoferrin  
wherein one aa has been substituted

&lt;400&gt; 86

Cys Phe Gln Trp Gln Arg Glu Met Arg Lys Val Arg  
1 5 10

&lt;210&gt; 87

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 20-31 in human lactoferrin  
wherein one aa has been substituted

&lt;220&gt;

&lt;223&gt; Xaa in position 5 is Orn

&lt;400&gt; 87

Cys Phe Gln Trp Xaa Arg Asn Met Arg Lys Val Arg  
1 5 10

&lt;210&gt; 88

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or artificial origin, corresp. to the sequence consisting of aa 20-31 in human lactoferrin wherein one aa has been substituted

<220>

<223> Xaa in position 5 is Nle

<400> 88

Cys Phe Gln Trp Xaa Arg Asn Met Arg Lys Val Arg  
1 5 10

<210> 89

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or artificial origin, corresp. to the sequence consisting of aa 20-31 in human lactoferrin wherein one aa has been substituted

<220>

<223> Xaa in position 7 is Orn

<400> 89

Cys Phe Gln Trp Gln Arg Xaa Met Arg Lys Val Arg  
1 5 10

<210> 90

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or artificial origin, corresp. to the sequence consisting of aa 20-31 in human lactoferrin wherein one aa has been substituted

<220>

<223> Xaa in position 7 is Nle

<400> 90

Cys Phe Gln Trp Gln Arg Xaa Met Arg Lys Val Arg  
1 5 10

<210> 91

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 20-31 in human lactoferrin  
wherein one aa has been substituted

<400> 91

Cys Phe Gln Trp Lys Arg Asn Met Arg Lys Val Arg  
1 5 10

<210> 92

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to a modification of  
the sequence consisting of aa 18-31 in human  
lactoferrin wherein one aa has been substituted

<220>

<221> MOD\_RES

<222> (1)

<223> ACETYLTATION

<220>

<221> MOD\_RES

<222> (12)

<223> AMIDATION

<400> 92

Cys Phe Gln Trp Lys Arg Asn Met Arg Lys Val Arg  
1 5 10

<210> 93

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 20-31 in human lactoferrin  
wherein some aa have been substituted

<400> 93

Cys Phe Gln Trp Lys Arg Ala Met Arg Lys Val Arg  
1 5 10

<210> 94

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 20-31 in human lactoferrin  
wherein some aa have been substituted

<400> 94

Cys Phe Ala Trp Lys Arg Asn Met Arg Lys Val Arg  
1 5 10

<210> 95

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 20-31 in human lactoferrin  
wherein some aa have been substituted

&lt;400&gt; 95

Cys Phe Ala Trp Gln Arg Ala Met Arg Lys Val Arg  
1 5 10

&lt;210&gt; 96

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to the sequence  
consisting of aa 20-31 in human lactoferrin  
wherein some aa have been substituted

&lt;400&gt; 96

Cys Phe Gln Leu Gln Lys Asn Met Lys Lys Val Arg  
1 5 10

&lt;210&gt; 97

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to a modification of  
the sequence consisting of aa 20-31 in human  
lactoferrin

&lt;400&gt; 97

Cys Phe Ala Leu Lys Lys Ala Met Lys Lys Val Arg  
1 5 10

&lt;210&gt; 98

&lt;211&gt; 14

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to a modification of



the sequence consisting of aa 18-31 in human  
lactoferrin

<220>

<221> MOD\_RES

<222> (1)

<223> ACETYLATION

<220>

<221> MOD\_RES

<222> (14)

<223> AMIDATION

<400> 98

Thr Lys Lys Phe Gln Trp Gln Arg Asn Met Arg Lys Val Arg

1

5

10

<210> 99

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: of natural or  
artificial origin, corresp. to a modification of  
the sequence consisting of aa 20-31 in human  
lactoferrin

<400> 99

Cys Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys Val Arg

1

5

10

<210> 100

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: a fragment of  
human lactoferrin consisting of aa 12-40

<400> 100

Val Ser Gln Pro Glu Ala Thr Lys Cys Phe Gln Trp Gln Arg Asn Met

1

5

10

15

WO 00/01730

PCT/SE99/01230

Arg Lys Val Arg Gly Pro Pro Val Ser Cys Ile Lys Arg  
20 25